SENSITIZATION OF PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS RESISTANT TO IMATINIB BY TARGETING SPHINGOLIPID METABOLISM

A Thesis Submitted to the Graduate School of Engineering and Sciences of İzmir Institute of Technology in Partial Fulfillment of the Requirements for the Degree of

DOCTOR OF PHILOSOPHY in Molecular Biology and Genetics

by Yağmur KİRAZ

November 2019
İZMİR
We approve the thesis of Yağmur KİRAZ

Examing Committee Members:

Prof. Dr. Yusuf BARAN
Department of Molecular Biology and Genetics, İzmir Institute of Technology

Prof. Dr. Bünyamin AKGÜL
Department of Molecular Biology and Genetics, İzmir Institute of Technology

Prof. Dr. Sevil DİNÇER İSOĞLU
Department of Bioengineering, Abdullah Gül University

Assoc. Prof. Dr. Özden YALÇIN ÖZUYŞAL
Department of Molecular Biology and Genetics, İzmir Institute of Technology

Prof. Dr. Ali ÜNAL
Department of Hematology, Erciyes University

15 November 2019

Prof. Dr. Yusuf BARAN
Supervisor, Department of Molecular Biology and Genetics, İzmir Institute of Technology

Prof. Dr. Bünyamin AKGÜL
Head of the Department of Molecular Biology and Genetics

Prof. Dr. Mehtap EANES
Dean of the Graduate School of Engineering and Sciences
ACKNOWLEDGMENTS

First and foremost, I would like to express my sincere appreciation to my supervisor Prof. Dr. Yusuf Baran for his support, guidance and encouragement throughout my PhD studies both in work environment and outside. It was truly a privilege for me to share of his academic successes but also of his extraordinary human qualities. I always will be grateful for the experiences that I have had while working with him.

A special thanks goes to Assoc. Prof. Dr. Chiara Luberto who has guided me with her scientific knowledge and always been encouraging and supportive whenever I feel needed during my studies. Her passion into science and excitement in regard to teaching has been a great motivation for me.

I would also like to thank Prof. Dr. Lina Obeid who gave me the chance to work in one of the pioneer laboratories in the field; The Lipid Cancer Lab in Health Science Center, Stony Brook University, NY, USA.

I want to thank to Prof. Dr. Yusuf A. Hannun for his valuable contributions and his comments throughout the project.

I want to thank the committee members; Prof. Dr. Bünnyamin Akgül, Prof. Dr. Sevil Dinçer İşoğlu, Assoc. Prof. Dr. Özden Yağcı Özyüsal and Prof. Dr. Ali Ünal for their contributions and constructive comments to my thesis.

I would like to thank to former and current graduate and undergraduate members of BARAN Lab; especially Nihan Aktaş, Gizem Tuğçe Ulu, Beyza Gürler and Erez Uzuner who were always been supportive. BARAN Lab is a great example of how to feel like a family in a professional environment.

I am also thankful to members of TLC Lab, who always have been helpful and answered all my questions with their experience and knowledge in the field. Also, I would like to thank Izolda Mileva, MS and Lipidomics Core Facility in Stony Brook University for their help in lipid experiments in this project.

Additionally, I thank to Jane Atallah, who worked with me and helped me with the experiments in TLC Lab, Dr. Sitapriya Moorthi for her constructive ideas and Gui-Qin for her helps when I needed.

I also thank Dr. Mona El Khatib who has been a great friend and an amazing example of a scientist for myself (also for her edits and contributions to my thesis). Also,
thanks to Pınar Karakaya, who has been the best friend anyone can ever ask for and supported me at every step of my life.

At last but not the least, I want to thank my mom Zekine Kiraz and my dad Abuzer Kiraz for their continuous support they have given me at every decision of mine throughout my life. Your love and encouragement are worth more than I can express on a paper.

This project was supported by TUBITAK BİDEB 2214-A International Research Fellowship Programme for PhD Students.
ABSTRACT

SENSITIZATION OF PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS RESISTANT TO IMATINIB BY TARGETING SPHINGOLIPID METABOLISM

Philadelphia positive acute lymphoblastic leukemia (Ph+ALL) is a common subtype of ALL and characterized by having BCR/ABL translocation. Tyrosine kinase inhibitors (TKI) such as imatinib are used for the treatment in Ph+ALL, however, 60-75% of the patients can develop resistance against the TKIs. Bioactive sphingolipids are a group of lipids that play roles in various cellular mechanisms. Previous studies showed that sphingolipids and genes in the pathway were involved in response to TKI treatment in Ph+ALL.

Here, we investigated the roles of SPL on the growth inhibitory effects of imatinib and exploit sphingolipid metabolism by majorly inhibiting glucosylceramide synthase (GCS) to accumulate ceramide or sphingosine to further sensitize cells to imatinib and/or overcome resistance to imatinib in Ph+ALL.

Firstly, we detected that sphingosine kinase-1 (SK-1) a well-studied SPL enzyme inhibition did not contribute to cytotoxic effects of imatinib in SD-1 Ph+ALL cells. Moreover, we determined that imatinib is inducing de novo synthesis pathway of SPL and increasing the levels of ceramide, sphingosine, hexosylceramides and sphingomyelin in SD-1 cells. Interestingly, newly generated imatinib-resistant cell line SD-1R was detected to have an aberration in this pathway resulting in development of resistance. Combination treatment with eliglustat (GCS inhibitor) resulted in a significant increase in ceramide and sphingosine levels and reflected on cell growth and sensitized cells to imatinib.

Taken together, it was shown for the first time in the literature that the cytotoxic effects of imatinib was due to induction of de novo synthesis pathway of sphingolipids and inhibition of GCS together with imatinib has synergistic cytotoxic effects on imatinib resistant Ph+ALL cells. As a conclusion, increasing the intracellular levels of ceramide (and/or sphingosine) can be a novel approach to sensitize drug resistant Ph+ALL cells.
ÖZET

SFİNGOLİPID METABOLİZMASININ HEDEFLENMESİYLE İMATİNİBE DIRENÇLİ PHILADELPHIA Pozitif Akut Lenfoblastik Lösemi Hücrelerinin Duyarlı Hale Getirilmesi

Philadelphia pozitif akut lenfoblastik lösemi (Ph+ALL), ALL’nin sıklıkla görülen bir alt tipi olmakla birlikte, BCR/ABL translokasyonunu taşımakla karakterizedir. Ph+ ALL tedavisinde, imatinib gibi tirozin kiraz inhibitörleri (TKİ) kullanılsa da, hastaların %60-75’i TKİ’lere karşı direnç gelişirmektedir. Biyoaktif sfingolipidler, birçok hücresel mekanizmada rol oynayan bir lipid grubudur. Daha önce yapılan çalışmalar biyoaktif sfingolipidlerin ve bu yol aktaki genlerin Ph+ALL’dede TKİ’ye verilen yanıtta rol aldığı göstermiştir.

Bu çalışmada, biyoaktif sfingolipidlerin imatinibin büyümeyi baskılayıcı rollerini ve sfingolipid metabolizmasından özellikle glukoizilseramid sentaz (GSS) ve sfingozin kinaz-1’i (SK-1) inhibe ederek seramid veya sfingozinin birikimine yol açarak hücreleri imatinibe duyarlı hale getirmeyi ve/veya direnci geri çevirmeyi araştırdık.

Öncelikle, daha önce çalışılmış bir sfingolipid enzimi olan SK-1 inhibisyonunun imatinibin SD-1 Ph+ALL hücreleri üzerine sitotoksik etkilerine katkı yapmadığını tespit ettik. Daha da önemlisi, imatinibin sfingolipid sentez yolu (de novo) sentez yolağını tetiklediğini ve seramid, sfingozin, heksozilseramid ve sfingomyelin düzeylerini arttırdığını belirledik. İlginç bir şekilde, yeni geliştirilen imatinib-dirençli SD-1R hücrelerinde bu yolakta tespit edilen bir anormallik direnç gelişimine neden olmuştur. Eliglustat (GSS inhibitörü) ile imatinibin kombinasyon tedavisi, seramid ve sfingozin seviyelerinde önemli artışa neden olarak, hücreleri imatinibre duyarlı hale getirdi.

Tüm bu veriler değerlendirildiğinde, imatinibin sitotoksik etkilerinin de novo sentez yolağını aktifleştirmesi ile olduğu ve GSS inhibisyonu ile imatinib uygulamasının imatinib-dirençli Ph+ALL hücrelerinde sinerjik sitotoksik etkileri olduğu literatürde ilk defa bu çalışma ile gösterilmiştir. Sonuç olarak, hücre içi seramid (ve/veya sfingozin) düzeylerinin artırılması, ilaç dirençli Ph+ALL hücrelerinin duyarlı hale getirilmesi için yeni bir yaklaşıma olabilir.
To my beloved family,

and to the greatest journey started
in 41°00'43.7"N 28°57'32.9"E …
# TABLE OF CONTENTS

**LIST OF FIGURES** .............................................................................................................. xi

**LIST OF TABLES** ............................................................................................................... xiv

**CHAPTER 1. INTRODUCTION** ..................................................................................... 1

1.1. Acute Lymphoblastic Leukemia ................................................................ 1

1.2. Philadelphia Positive Acute Lymphoblastic Leukemia ............................. 4

1.3. Treatment of Philadelphia Positive Acute Lymphoblastic Leukemia ...... 5

1.3.1. Standard Chemotherapy ...................................................................... 5

1.3.2. Targeted Therapy (Tyrosine Kinase Inhibitors) ................................. 6

1.3.2.1. Imatinib ........................................................................................ 6

1.3.2.2. Nilotinib and Dasatinib ................................................................ 8

1.3.2.3. Ponatinib .................................................................................... 10

1.3.3. Monoclonal Antibodies & Immunotherapy ...................................... 11

1.3.4. Stem Cell Transplant ......................................................................... 12

1.4. Resistance to Tyrosine Kinase Inhibitors ................................................ 13

1.4.1. BCR/ABL Mutations ........................................................................ 14

1.4.2. Gene Amplifications ......................................................................... 15

1.4.3. Genomic Deletions ............................................................................ 16

1.4.4. Alterations in Protein Expression ..................................................... 17

1.4.5. Activation of Alternative Signaling Pathways ................................. 18

1.4.6. Alterations in Drug Influx/Efflux Mechanisms ................................ 20

1.5. BCR/ABL Signaling Mechanisms ........................................................... 21

1.6. Bioactive Sphingolipids ........................................................................... 24

1.6.1. Ceramide Metabolism and Signaling ............................................... 27

1.6.2. Antiproliferative Roles of Ceramide ............................................... 29

1.6.3. Bioactive Sphingolipids in Drug Resistance in Cancer ................. 31

1.6.4. Targeting Sphingolipid Signaling in Cancer Therapy .................... 33

1.6.5. Targeting Sphingolipid Metabolism for the Treatment of Hematological Malignancies ............................................................ 35

1.7. Aim of the Project .................................................................................... 37
CHAPTER 2. MATERIALS AND METHODS ............................................................ 39

2.1. Chemicals and Reagents ........................................................................ 39
2.2. Cell Lines and Culture Conditions ......................................................... 39
2.3. Thawing Frozen Cells ............................................................................ 40
2.4. Maintenance of CCRF-CEM, SUP-B15 and SD-1 Cell Lines ............... 40
2.5. Freezing Cells ....................................................................................... 40
2.6. Generation of Imatinib Resistant SD-1R cells ........................................ 41
2.7. Treatment with Imatinib and/or Other Inhibitors ................................... 41
2.8. Treatment with Exogenously Added Sphingolipids ............................. 42
2.9. Determining Cell Viability with Trypan Blue Exclusion Assay .......... 42
2.10. Measuring Cell Proliferation by MTT Assay ......................................... 42
2.11. Protein Isolation and Preparation ....................................................... 43
2.12. Protein Quantification by BCA Assay .................................................. 43
2.13. Western Blotting .................................................................................. 44
2.14. RNA Isolation ...................................................................................... 44
2.15. Quantification of RNA ......................................................................... 45
2.16. cDNA Synthesis .................................................................................. 45
2.17. Real Time Quantitative PCR ............................................................... 46
2.18. siRNA Transfection ............................................................................ 46
2.19. Lipid Analysis by HPLC/MS/MS ........................................................... 47
2.20. Determination of Inorganic Phosphate (Pi) Concentrations ............... 47
2.21. Measuring In situ GCS Activity by NBD-C6-Ceramide Labeling ....... 49
2.22. Measuring In situ SK Activity by NBD-Sphingosine Labeling .......... 50
2.23. Statistical Analyses ............................................................................. 50

CHAPTER 3. RESULTS ................................................................................................ 51

3.1. SD-1 Ph+ ALL Cells Show Intrinsic Resistance to Imatinib ............... 51
3.2. SK-1 Inhibition Does Not Contribute to Cytotoxic Effects of Imatinib... 53
3.3. Endogenous Sphingolipid Levels are Elevated in Response to
    Imatinib in SD-1 Cells ............................................................................ 58
3.4. Endogenous Complex Sphingolipid Levels are Elevated in Response
    to Imatinib in SD-1 Cells ....................................................................... 61
<table>
<thead>
<tr>
<th>Figure</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.1. Formation of Philadelphia chromosome</td>
<td>5</td>
</tr>
<tr>
<td>Figure 1.2. Sphingolipid synthesis and metabolism</td>
<td>25</td>
</tr>
<tr>
<td>Figure 1.3. Major sphingolipids and their involvement into cellular mechanisms</td>
<td>28</td>
</tr>
<tr>
<td>Figure 2.1. Generation of resistant cell line (SD-1R) by clonal selection</td>
<td>41</td>
</tr>
<tr>
<td>Figure 3.1. Determining the effect of imatinib on the viability of Ph+ ALL cell lines</td>
<td>52</td>
</tr>
<tr>
<td>Figure 3.2. Determining the effect of imatinib on the proliferation of SD-1 cell line</td>
<td>52</td>
</tr>
<tr>
<td>Figure 3.3. Analysis of SK activity in response to increased concentrations of PF543 by HPLC</td>
<td>55</td>
</tr>
<tr>
<td>Figure 3.4. Quantification of SK activity in response to increased concentrations of PF543</td>
<td>56</td>
</tr>
<tr>
<td>Figure 3.5. The protein levels of SK-1 and SK-2 treated with imatinib, PF543 and SKI-II by western blotting</td>
<td>56</td>
</tr>
<tr>
<td>Figure 3.6. SK activity in response to imatinib treatment, PF543 and their combination</td>
<td>57</td>
</tr>
<tr>
<td>Figure 3.7. Determining the effect of imatinib, PF543 and their combination on cell viability on SD-1 cell line</td>
<td>57</td>
</tr>
<tr>
<td>Figure 3.8. Analysis of endogenous ceramide levels of SD-1 cells in response to imatinib (most abundant species)</td>
<td>59</td>
</tr>
<tr>
<td>Figure 3.9. Analysis of endogenous ceramide levels of SD-1 cells in response to imatinib (less abundant species)</td>
<td>59</td>
</tr>
<tr>
<td>Figure 3.10. Analysis of endogenous ceramide levels of SD-1 cells in response to imatinib (the least abundant species)</td>
<td>60</td>
</tr>
<tr>
<td>Figure 3.11. Analysis of endogenous sphingolipid levels of SD-1 cells in response to imatinib</td>
<td>60</td>
</tr>
<tr>
<td>Figure 3.12. Analysis of endogenous hexosylceramide levels of SD-1 cells in response to imatinib (most abundant species)</td>
<td>62</td>
</tr>
<tr>
<td>Figure 3.13. Analysis of endogenous hexosylceramide levels of SD-1 cells in response to imatinib (less abundant species)</td>
<td>63</td>
</tr>
<tr>
<td>Figure 3.14. Analysis of endogenous sphingomyelin levels of SD-1 cells in response to imatinib (most abundant species)</td>
<td>63</td>
</tr>
</tbody>
</table>
Figure 3.15. Analysis of endogenous sphingomyelin levels of SD-1 cells in response to imatinib (less abundant species) ............................................................ 64

Figure 3.16. Analysis of endogenous sphingomyelin levels of SD-1 cells in response to imatinib (the least abundant species) ..................................................... 64

Figure 3.17. Analysis of de novo sphingolipids in response to myriocin;
A. dihyrdroC16-ceramide levels, B. dihydroceramide levels .................. 65

Figure 3.18. The changes in total ceramide levels with imatinib treatment in presence of myriocin .................................................................................. 66

Figure 3.19. The changes in sphingosine levels with imatinib in presence of myriocin .................................................................................................... .67

Figure 3.20. The changes in total hexosylceramide levels with imatinib in presence of myriocin .................................................................................. 68

Figure 3.21. The changes in total sphingomyelin levels with imatinib in presence of myriocin .................................................................................. 68

Figure 3.22. Contribution of de novo sphingolipid pathway to cytotoxic effects of imatinib in SD-1 cells ......................................................................... 70

Figure 3.23. The effect of exogenous treatment with C6-ceramide on cell viability ..... 70

Figure 3.24. The effect of exogenous treatment with sphingosine on cell viability ...... 71

Figure 3.25. The effects of eliglustat treatment on GCS activity measured by production of A. NBD-C6-hexosylceramide and B. hexosylceramides .... 72

Figure 3.26. The changes in the total ceramide levels of SD-1 cells treated with imatinib and eliglustat and their combination ............................................ 73

Figure 3.27. The changes in the total hexosylceramide levels of SD-1 cells treated with imatinib and eliglustat and their combination .................................. 74

Figure 3.28. The changes in the total sphingomyelin levels of SD-1 cells treated with imatinib and eliglustat and their combination .................................. 75

Figure 3.29. The changes in the sphingosine levels of SD-1 cells treated with imatinib and eliglustat and their combination ............................................. 76

Figure 3.30. The effect of treatment with imatinib, eliglustat and their combination on cell viability of SD-1 cells ............................................................. 77

Figure 3.31. The effects of GCS siRNA transfection on GCS activity measured by A. GCS mRNA levels and B. NBD-C6-hexosylceramide levels ....... 78
Figure 3.32. Effect of GCS knockdown and imatinib treatment on the levels of hexosylceramides in SD-1 cells ................................................................. 79

Figure 3.33. Effect of GCS knockdown and imatinib treatment on the levels of ceramide in SD-1 cells ............................................................................... 79

Figure 3.34. Effect of GCS knockdown and imatinib treatment on the levels of sphingomyelin in SD-1 cells ........................................................................ 80

Figure 3.35. Effect of GCS knockdown and imatinib treatment on the levels of sphingosine in SD-1 cells ........................................................................ 81

Figure 3.36. Effect of GCS knockdown together with imatinib treatment on cell viability in SD-1 cells ............................................................................. 81

Figure 3.37. Comparative response to imatinib treatment by SD-1 and SD-1R cells measured by A. trypan blue assay B. MTT assay ................................. 83

Figure 3.38. Mechanism of resistance to apoptosis induced by imatinib in SD-1R cells A. Cleaved caspase-3 B. BCL2 and BCL-XL C. BCR/ABL levels .... 84

Figure 3.39. Changes in endogenous ceramide levels of SD-1 and SD-1R cells in response to imatinib ................................................................. 85

Figure 3.40. Changes in endogenous hexosylceramide levels of SD-1 and SD-1R cells in response to imatinib ................................................................. 86

Figure 3.41. Changes in endogenous sphingosine levels of SD-1 and SD-1R cells in response to imatinib ................................................................. 86

Figure 3.42. Changes in endogenous sphingomyelin levels of SD-1 and SD-1R cells in response to imatinib ................................................................. 87

Figure 3.43. The changes in the hexosylceramide levels of SD-1R cells treated with imatinib and eliglustat and their combination ................................................. 88

Figure 3.44. The changes in the ceramide levels of SD-1R cells treated with imatinib and eliglustat and their combination ................................................. 89

Figure 3.45. The changes in the sphingosine levels of SD-1R cells treated with imatinib and eliglustat and their combination ................................................. 89

Figure 3.46. The effect of treatment with imatinib, eliglustat and their combination on cell viability of SD-1R cells ................................................................. 90

Figure 3.47. Effect of GCS knockdown together with imatinib treatment on cell viability in SD-1R cells ............................................................................. 91
## LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.1. WHO classification of ALL</td>
<td>2</td>
</tr>
<tr>
<td>Table 2.1. Preparation of diluted bovine serum albumin (BSA) standards</td>
<td>43</td>
</tr>
<tr>
<td>Table 2.2 Annealing mixture of the cDNA preparation protocol</td>
<td>45</td>
</tr>
<tr>
<td>Table 2.3. The enzyme mix used in cDNA synthesis</td>
<td>46</td>
</tr>
<tr>
<td>Table 2.4. Standards used in inorganic phosphate determination</td>
<td>49</td>
</tr>
</tbody>
</table>
1.1. Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is a type of hematological cancer that arises from the lymphoid lineage of blood cells and is characterized by the accumulation of large numbers of immature lymphocytes. Different genetic and environmental factors have been identified to have predisposing roles in the disease progression. Down syndrome, Bloom syndrome and ataxia talangiectasia are the commonly known genetic abnormalities that have been identified in ALL cases together with certain virus infections such as Human Immunodeficiency Virus (HIV) and Epstein-Barr Virus (EBV). However, majority of ALL cases occur de novo as acute malignancies.\(^1\-^3\).

Acute lymphoblastic leukemia is the most common childhood cancer. It is detected in 80% of childhood leukemias, on the other hand, it represents 20% of adult leukemias. Statistically, it is seen in 1.6-1.7 adults while 4-5 children per 100,000 population. In 2019, an estimated 5,930 number of new cases are reported together with 1,500 deaths from ALL only in the United States.\(^4\) Although the advancements and intensification of the therapy led to improvements in the responses of pediatric patients, however, the prognosis of adults remains very poor. Most of the patients show response to induction therapy but only 30-40% of them are able to sustain long-term remission.\(^1\)

The main characteristics of ALL is the accumulation of immature lymphoid cells in the bone marrow and peripheral blood. As a result of this abnormality, each patient can have their own specific or combination of different symptoms such as anemia, leukopenia and/or thrombocytopenia, easy bleeding or bruising and fatigue.\(^5\-^7\)

ALL diagnosis requires the presence of at least 20% of lymphoblasts in the bone marrow and peripheral blood. Diagnosis is confirmed and the disease is sub-specified by additional tests on cell morphology, genetic markers, cytogenetic tests and immunophenotyping.\(^5\,^8\)
Initially, the classification of ALL was performed by following the French American British (FAB) criteria that grouped ALL into 3 subtypes (L1, L2 and L3) based on morphological features \(^9\). Later on, the World Health Organization (WHO) International panel recommended to revoke this classification since it does not reflect clinical prognosis, immunophenotype or genetic abnormalities. WHO proposed an alternative classification that comprises morphological and cytogenetic features of lymphoblasts that divided ALL into 3 subtypes: B lymphoblastic, T lymphoblastic and Burkitt-cell leukemia \(^{10,11}\). Although Burkitt-cell leukemia was excluded in the revision in 2008, B-lymphoblastic type of ALL was divided into another two subtypes as follows: B-lymphoblastic leukemia with recurrent genetic abnormalities and B-lymphoblastic leukemia not otherwise specified. Current subclassification of ALL according to 2016 WHO baseline is shown in Table 1 \(^{12}\). Majority of the ALL cases is comprised by B-cell ALL whereas T-cell ALL only accounts for 25% of cases.

### Table 1. WHO classification of ALL

<table>
<thead>
<tr>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-cell lymphoblastic leukemia/lymphoma – not otherwise specified</td>
</tr>
<tr>
<td>B-cell lymphoblastic leukemia/lymphoma, with recurrent genetic abnormalities</td>
</tr>
<tr>
<td>B-cell lymphoblastic leukemia/lymphoma with hypodiploidy</td>
</tr>
<tr>
<td>B-cell lymphoblastic leukemia/lymphoma with hyperdiploidy</td>
</tr>
<tr>
<td><strong>B-cell lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2)[BCR-ABL1]</strong></td>
</tr>
<tr>
<td>B-cell lymphoblastic leukemia/lymphoma with t(v;11q23)[MLL rearranged]</td>
</tr>
<tr>
<td>B-cell lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22)[ETV6-RUNX1]</td>
</tr>
<tr>
<td>B-cell lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3)[TCF3-PBX1]</td>
</tr>
<tr>
<td>B-cell lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32)[IL3-IGH]</td>
</tr>
<tr>
<td>B-cell lymphoblastic leukemia/lymphoma with intrachromosomal amplification of chromosome 21 (iAMP21)</td>
</tr>
<tr>
<td>B-cell lymphoblastic leukemia/lymphoma with translocations involving tyrosine kinases or cytokine receptors (BCR-ABL1–like ALL)</td>
</tr>
<tr>
<td>T-cell lymphoblastic leukemia/lymphomas</td>
</tr>
<tr>
<td>Early T-cell precursor lymphoblastic leukemia</td>
</tr>
</tbody>
</table>

Risk stratification and prognosis assessment are the key factors to administer the most suitable treatment for the patients. Clinicians usually rely on the patients' age and white blood cell (WBC) count to decide the treatment regimen and its duration if the patient is suitable for stem cell transplantation (SCT). Poor prognosis is usually seen in patients >60 years old with 10-15% survival rate. This is mainly due to the increase in the
frequency of chromosomal abnormalities, hypodiploidy, complex karyotype and medical comorbidities with age. The largest prospective study to determine the optimal induction therapy for adult ALL patients was MRC UKALL XII/ECOG E2993 and it was completed in 2005 with the participation of more than 1500 patients. In this study, they reported that the overall survival (OS) rate of the patients who were able to go through complete remission (CR) was 45%. However, for the other patients who did not achieve CR, the survival rate was 5%. On the other hand, they determined that the prognosis is directly proportional with the age factor, such that the younger the patients are, the more efficient the treatment is. Additionally, they reported that having less than 30x10^9 WBC/L count for B-ALL and 100x10^9 WBC/L count for T-ALL is another factor that contributes to OS and disease-free survival (DFS) rates in the patients. These results, have led to the categorization of the Philadelphia negative ALL as follows: i) low risk (age <35 and low WBC count) with having 55% OS rate ii) intermediate risk (age >35 or high WBC count) with 34% OS rate and iii) high risk with 5% OS rate (both age >35 and high WBC count).

As much as the clinical factors and risk stratification is of primary importance to therapy, genetic changes can be a major determinant for the prognosis of ALL. Many different cytogenetic abnormalities and chromosomal translocations have been identified in ALL. The most frequently detected genetic abnormalities are: t(12;21) [ETV6-RUNX1], t(1;19) [TCF3-PBX1], t(9,22) [BCR-ABL1] (Philadelphia positive). More recently, a new group of patients have been identified, who carry a similar profile to BCR-ABL positive ALL but without having the BCR-ABL1 translocation. This group of patients is defined as Ph-like ALL and have poor prognosis somewhat similar to Ph-positive ALL patients. Ph-like ALL represents 10% of the childhood ALL, while it is about 25-30% of the cases in young adults. More than 80% of the Ph-like ALL cases contains deletions in major transcription factors that are involved in B-cell maturation/development such as IKAROS family zinc finger 1 (IKZF1), early B-cell factor 1 (EBF1), transcription factor 3 (E2A) and paired box 5 (PAX5). Additionally, kinase-activating alterations including rearrangements of ABL1, ABL2, Janus kinase 2 (JAK2), erythropoietin receptor (EPOR), cytokine-receptor-like factor 2 (CRLF2), fms-related tyrosine kinase 3 (FLT3), interleukin 7 receptor (IL7R), SH2B3 have been identified in a great majority of the cases in Ph-like ALL.
1.2. Philadelphia Positive Acute Lymphoblastic Leukemia

Philadelphia positive, also known as BCR/ABL positive acute lymphoblastic leukemia (Ph+ ALL), is the most common subtype of B-ALL detected in adults. It represents 25-30% of the adult ALL cases whereas only seen in about 5% of childhood ALL. The incidence of Ph+ ALL reaches up to 50% in patients over 60 years old 19. Patients are presented with high but variable white blood cell (WBC) count and splenomegaly together with other symptoms such as fatigue, dizziness, etc. 20.

The characteristics of the disease is having a reciprocal translocation that occurs between ABL1 gene that is located on the long arm of chromosome 9 and breakpoint cluster region (BCR) gene that is located on the long arm of chromosome 22. As a result, a fusion transcript, which eventually encodes BCR/ABL, is produced by the newly formed Philadelphia chromosome, It can be detected by molecular methods such as polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH) analysis 21. Newly formed BCR/ABL protein has a constitutive kinase activity, which leads to the activation of multiple signaling pathways in the cells that are involved in the regulation of several cellular processes such as, cell proliferation, growth and survival. BCR/ABL protein can be found in various sizes depending on the breakpoint in BCR gene that results indifferent BCR isoform proteins with the following sizes 190, 210 and/or 230 kDa. The p210 BCR/ABL transcript is usually observed in chronic myeloid leukemia (CML) and in a minor portion of Ph+ ALL cases, whereas p190 BCR/ABL transcript is detected in majority of Ph+ ALL patients. Co-presence of both p190 and p210 BCR/ABL might be detected in some rare cases 21,22. The presence of BCR/ABL is known to enhance some of the hallmarks of cancer such as resistance to cell death, being independent from growth factors and alterations in cell-cell interactions, thus resulting in a more aggressive clinical course.

Ph+ ALL is almost always found among B-lymphoblastic ALL except for a few reported cases with T-lymphoblastic ALL. Leukemic lymphoblasts can be distinguished based on the detection of a higher expression of CD34 cell surface marker and some (10-20%) myeloid markers 23. Almost in 70% of the cases, additional chromosomal abnormalities including monosomy 7 or hyperdiploid karyotypes have been detected together with BCR/ABL translocation in Ph+ ALL 20.
1.3. Treatment of Philadelphia Positive Acute Lymphoblastic Leukemia

The treatment of Ph+ ALL can be categorized into two as follows: pre-tyrosine kinase inhibitors (TKI) era and post-tyrosine kinase inhibitors era. The latter has started with the introduction of the first tyrosine kinase inhibitor imatinib in 2001 and followed by development of newer technologies 24.

1.3.1. Standard Chemotherapy

Ph+ ALL patients that were given standard chemotherapy regimen without addition of TKIs to the therapy had shown very poor prognosis. Although chemotherapy is able to achieve complete remissions (CR) in more than 70% of the patients, relapse is seen in most of the patients within 6 months followed by death due to the disease 20. The 5-year overall survival (OS) rates were no more than 10%. Notably, hyper-CVAD chemotherapy, which is a cocktail of cyclophosphamide, vincristine, doxorubicin and
dexamethasone alternating with methotrexate and cytarabine, was able to achieve 91% of CR rate together with an estimated 39% of 5-year OS. However, in the long run, survival rates were similar, thus highlighting the need to develop and come up with new treatment options for Ph+ ALL.

1.3.2. Targeted Therapy (Tyrosine Kinase Inhibitors)

Understanding the role and the mechanism of action of BCR/ABL led to the development of new tyrosine kinase inhibitors (TKIs), such as imatinib mesylate, which is the first-generation TKI. Identification of imatinib later on was followed by development of dasatinib and nilotinib as second-generation TKIs and finally by ponatinib as third-generation TKI. The common mechanism of action of these TKIs is to block the binding of adenosine triphosphate (ATP) to the ATP binding site of BCR/ABL which will eventually prevent the signal transduction toward downstream pathways of BCR/ABL. BCR/ABL is known to activate multiple signaling pathways in the downstream including Ras, MAPK, Src, PI3K, Jak/STAT pathways. Targeting BCR/ABL activity by TKIs results in blockage in the signals through these major signaling pathways which eventually prevents cell proliferation and cancer progression. Introduction of TKIs into the therapy regimen has led to a revolution in the treatment of Ph+ ALL. The usage of each TKI alone or in addition to chemotherapy regimen is explained in the next sections with their expected and/or reported outcomes.

1.3.2.1. Imatinib

The approval of imatinib (Gleevec® or Glivec®) in 2001 was a breakthrough that started a new era in cancer treatment. It was first discovered in the late 90s by Nicholas Lyndon, a biochemist and was suggested by Brian Druker, an oncologist to be used in CML treatment. In 1998, the first clinical trial of imatinib was completed and followed by the Food and Drug Administration's (FDA) approval in 2001. After overt effect of
imatinib for the treatment of CML patients, the research was driven toward the usage of imatinib in other cancers, which then showed success in cancers that harbored an overexpression in tyrosine kinases 24.

Imatinib is a 2-phenyl amino pyrimidine derivative and works as a tyrosine kinase inhibitor targeting BCR/ABL, ABL, PDGFR and c-Kit kinase activities. The mode of action of tyrosine kinases is through a process referred to as protein tyrosine phosphorylation: the transfer of one phosphate (Pi) from ATP to the tyrosine residues on the substrate. Imatinib acts by binding to the ATP binding site, therefore keeping the conformation inhibited, which results in the inhibition of enzymatic activity 24,27. Since BCR/ABL and other kinases activates multiple downstream signaling pathways, which will eventually induce leukemogenesis, this signal transformation to downstream signaling is blocked by imatinib treatment. Additionally, imatinib inhibits the entry of BCR/ABL into the nucleus, where it exhibits its anti-apoptotic functions 28.

Imatinib is rather used as a combination with standard chemotherapy in Ph+ ALL treatment, where it has increased CR rates above 90% and 5-year OS rates up to 50 29–31.

In a more recent phase II trial completed with 54 older patients (median age of 51), the patients were treated with the combination of imatinib with hyperfractionated cyclophosphamide, vincristine, Adriamycin and dexamethasone (hyper-CVAD), showing a 93% of CR rate with 45% of complete molecular remission (CMR) at 3-months. Although a small portion of the patients (30%) went through allogenic hematopoietic stem cell transplantation (alloHSCT) in first CR, still the 5-year OS reached up to 43%, which was significantly higher than the previously reported rates 6.

In another important clinical study: UKALLXII/ECOG2993, 441 newly diagnosed adult Ph+ ALL patients were enrolled into 3 groups as follows: 266 patients in pre-imatinib group in which the patients were not given imatinib at all during chemotherapy; 86 patients in late imatinib group where the patients were given imatinib alone right after 2 induction courses and 89 patients in early imatinib group in which imatinib was added into the second phase of induction course. It was reported that imatinib cohort has remarkably higher rates of CR, being 92% together with higher 4-year OS, compared to pre-imatinib cohort, which is showing 82% CR rates. Importantly, early introduction of imatinib showed further increase in the 4-year OS as 43%. They also reported that alloHSCT is still favored at the post-induction stage in Ph+ ALL no matter if the patients are given imatinib 30.
Imatinib has also been used in combination with reduced-intensity chemotherapy to see its feasibility for these conditions. For this purpose, the GRAAPH-2005 trial was designed to include the following cohorts: imatinib combined with reduced chemotherapy (including only vincristine and dexamethasone) and imatinib with hyper-CVAD chemotherapy. The reduced intensity group showed higher CR rate (98%) compared to hyper-CVAD cohort (91%), which is thought to be due to the higher rate of induction deaths in hyper-CVAD group (being 6% vs. 1%). Moreover, 63% of the responsive patients were taken under alloHSCT and 14% of them went to autologous HSCT (autoHSCT), which then showed 37% and 46% OS, respectively without any correlation to the type of transplantation.

The introduction of imatinib into the treatment regimen of Ph+ ALL have led to great advancements in the treatment of this deadly disease. However, despite this great improvement in therapy patients have developed resistance to imatinib, which necessitated the development of new treatments options for Ph+ ALL and hence the discovery of the next generation TKIs. Despite the fact that newer technologies have been developed and currently used in the clinics, imatinib resistance stands as the most challenging phenomenon in the treatment of Ph+ ALL together with causing the most share of mortalities. Since imatinib, in most of the countries, is still used in the first-line treatment, patients’ prognosis mostly relies on their response to imatinib treatment. The mechanism of imatinib resistance will be detailed in the following sections together with possible actions against resistance and strategies to overcome imatinib resistance as well as sensitizing cells/patients to treatment.

### 1.3.2.2. Nilotinib and Dasatinib

A second generation TKI Nilotinib (Tasigna®) is structurally derived from imatinib. It has the inhibitory effect against BCR/ABL, c-Kit and PDGFR as imatinib does and shows 20-50-fold more potency than imatinib. Although it has not received the FDA approval for its use in Ph+ ALL, clinical trials have continuously been going on for the patients that are showing imatinib resistance. In a phase II clinical study, nilotinib was used as monotherapy in Ph+ ALL patients who were relapsed or refractory resulted in
24% of CR rates. On the other hand, combination of nilotinib with chemotherapy including vincristine, daunorubicin and prednisolone was investigated by a multicentric study and the results showed remarkably high CMR (94%) and 2-year relapse-free survivals (72%) 33.

In another cohort study, EWALL, nilotinib was used in combination with reduced-intensity chemotherapy for the newly diagnosed Ph+ ALL patients. The results showed higher efficacy in patients older than 55 years in addition to 87% CR rates in these patients. Additionally, the OS was 73% at the follow-up of 8.5 months 34.

The results of the most recent trial, GRAAPH-2014, in which the patients (median age of 47 years old) were given nilotinib with reduced-intensity chemotherapy, showed 98% of CR rates together with 93% cumulative molecular response rate. The percentage of the patients who underwent alloHSCT was 73% in CR1 stage. This study carries importance in terms of shaping the treatment strategy for younger patients to see if combining nilotinib with low-intensity chemotherapy followed by alloHSCT shows better outcome for those patients 35.

Another second-generation TKI, dasatinib (Sprycel®), is considered to be rather more a pan-TKI rather than only targeting ABL kinase. It also inhibits src, c-Kit, PDGFR and ephrin receptor kinases. Dasatinib differs from the other TKIs by having the ability of binding to both the active and inactive conformations of ABL and by targeting most of the TKI resistance-causing mutations in the kinase domains of ABL except for T315I mutation. Using dasatinib for Ph+ ALL patients has been approved by FDA for the patients who are intolerant to prior imatinib treatment in 2006. It has also been approved by FDA for the newly diagnosed pediatric patients in 2018 26,36,37. In a phase II clinical study, dasatinib was given as a monotherapy for the patients who are resistant or intolerant to imatinib and the results showed 58% of the patients in complete cytogenetic remission (CCyR) 38. In another multicentric phase II trial, imatinib resistant or intolerant CML patients achieved 35% and 52% CR rates, respectively, by dasatinib treatment 26. The results from clinical trials were mostly short-lived with maximum 3-months of progression free survival (PFS) rates. Hereupon, another study was designed to combine dasatinib with standard chemotherapy in the frontline treatment. In this phase II trial, newly diagnosed Ph+ ALL patients (median age 55 years old), were given dasatinib with hyper-CVAD chemotherapy. It was reported that the CR rate reached up to 96% in addition to 83% CCyR rates and 65% CMR rates. The patients also showed 44% of relapse free survival (RFS) and 46% of OS rates 39.
Notably, intensive chemotherapy is not well tolerated in all patients. In some studies, it has been shown that moderate toxicity can be tolerated in elderly patients in which neither intense chemotherapy nor alloHSCT was used \(^{40,41}\). In a clinical study, GIEMMA group, dasatinib was combined with only prednisone for the newly diagnosed Ph+ ALL patients and the results showed CR for all the patients. Additionally, MMR was increasing gradually day by day and eventually achieving 52% at the end of induction course \(^{40}\).

In another study, similar results were observed for the patients who received dasatinib in combination with steroids. They reported 97% of CHR rate together with a successfully achieved CMR in 19% of the patients. On the other hand, the patients who did not achieve CMR underwent chemotherapy or alloHSCT. Together, there was 58% of 3-year OS was observed for the patients \(^{41}\).

In another international study, EWALL-PH-01, dasatinib was used again in combination with reduced-intensity chemotherapy (only vincristine and dexamethasone in induction; L-asparaginase, methotrexate and cytarabine in consolidation courses) for elderly patients who are over 55 years old. Although 96% of the patients achieved CR with 65% of MMR; OS was reported as 36%. After the CR, only 10% of the patients received alloHSCT, which proves that remission (with moderate long-term survival) is achievable for the elderly patients without intensive chemotherapy or alloHSCT \(^{42}\). Although better responses were reported with dasatinib treatment, the fact that it could not target BCR/ABL with T315I mutation brought out the need for new generation tyrosine kinase inhibitors.

1.3.2.3. Ponatinib

Ponatinib (Iclusig\textsuperscript{®}) is a third generation TKI after imatinib and dasatinib that was approved by FDA for its use in Ph+ ALL. In addition to its inhibitory effect on BCR/ABL by 520-times more potency; it also inhibits VEGFR, FGFR, ephrin, src, c-Kit, RET and FLT3. The novelty of ponatinib among other TKIs is due to its ability to target different mutations in the BCR/ABL kinase domain including the T315I, a point mutation which represents one of the major causes of TKI resistance. Notably, these mutations are
identified in 37% of the patients at the time of diagnosis before the initiation of treatment\textsuperscript{43,44}.

In the study by Rousselot et al. they showed T315I mutation that was identified during diagnosis was correlated with early relapses in patients \textsuperscript{42}.

In the clinical trials, ponatinib treatment for the patients who are resistant to earlier generation TKIs or carrying T315I mutation, resulted in 38% of CCyR rate and led to a 40% of 1-year OS rate. Ponatinib was also tried in combination with hyper-CVAD chemotherapy by a single-institution phase II study which showed the highest success rates reported so far in the field in terms of CR and OS rates. Their results showed 97% CR rate and no detection of minimal residual disease (MRD). Initial results also showed an estimated 2-year OS by 80% which then was updated by 97% of CR rates in the following study, together with 77% of CMR at the median follow-up of 33 months \textsuperscript{45,46}.

In the GIEMMA LAL 1811 trial, ponatinib was used in combination with corticosteroids for the elderly/unfit patients. A remarkable portion of the patients (95%) achieved CHR right after the first cycle. This study also reported 45.8% of CMR rates in patients after ponatinib treatment, which was more than what had been reported in the dasatinib and corticosteroids study \textsuperscript{26}.

On the other hand, despite the documented high response by the patients; the concern about the adverse side effects of ponatinib such as heart failures, vascular and arterial problems is still newsworthy and a limitation for the long-term / high concentration usage of ponatinib for patients \textsuperscript{47}. Therefore, ponatinib is avoided as much as possible in the clinics except for the patients who already failed previous therapies.

1.3.3. Monoclonal Antibodies & Immunotherapy

Monoclonal antibodies have been recently used as a novel therapy for the treatment of B-ALL. Antibodies targeting the specific markers that are overexpressed in Ph+ ALL lymphoblasts such as, CD19, CD20, CD22 are designed and used as treatment. They can be used in combination with hyper-CVAD chemotherapy and TKI; in such anti-CD20 monoclonal antibody rituximab was tested in a study. The results showed the
patients showed better outcome compared to the ones that received the standard treatment in previous studies 48.

Another monoclonal antibody, inotuzumab ozogamicin, which is against CD22, was tested in relapsed Ph+ ALL patients and resulted in no significant changes between standard therapy and inotuzumab cohort 49.

On the other hand, blinatumomab, which is designed to bind CD19 and CD3 bispecifically, has become the most promising monoclonal antibody with significant results in high-risk ALL patients and in Ph+ ALL patients who carry T315I mutation. The results showed 40% of CR rate in the patients with T315I mutation. Additionally, this study showed that blinatumomab was able to reverse MRD status into negative 50,51.

An important breakthrough has been achieved in immunotherapy for cancer treatment, which is the development of chimeric antigen receptor T cell (CAR T-cell). CAR T-cell treatment is basically a strategy in which T-cells are taken from the patients and modified in the laboratory to express a receptor specific for a tumor antigen, after which it is re-infused back to the patient. These CARs are made up of fusion proteins of one specific monoclonal antibody against the cancer cells and one/more T-cell receptor intracellular domain.

Recently, CAR T-cell clinical trials have been going on for different hematological cancers and showing remarkably promising results 52. Although the technology is too recent to report long-term outcomes, some studies are suggesting promising results also for Ph+ ALL patients. In a recent study, CD19 targeting CAR T-cells for concurrent chronic lymphocytic leukemia (CLL) and Ph+ ALL, The patient in this study showed reduced levels of detectable BCR/ABL along with no detectable MRD signatures 53.

1.3.4. Stem Cell Transplant

Stem cell transplant is a clinical procedure for patients in which healthy stem cells are transplanted into the patients to regenerate healthy blood cells instead of the ones that are damaged by leukemogenesis or by intensive chemotherapy/radiotherapy. The main two types of transplants are allogenic and autogenic transplantation. In allogenic
transplantation (alloHSCT) the patient is given another individual’s stem cells. In this case, the donor’s bone marrow should match the patient’s bone marrow. This can be tested by checking human leukocyte antigens (HLA) on white blood cells. The importance of finding a matching donor is to prevent graft-versus-host-disease (GVHD) in which the healthy transplanted cells attack the patient’s cells. The higher the matching HLA score is the lower the GVHD can develop. On the other hand, in autologous transplantation (autoHSCT), the patients are given their own stem cells in which the healthy ones had been collected and selected from the bone marrow before the chemotherapy or radiotherapy starts 54.

Before imatinib was introduced into Ph+ ALL treatment, patients were only receiving multiagent chemotherapy, which did not exhibit promising outcomes. Patients were undergoing alloHSCT, in case there was an available donor, right after they reach first remission. Patients who have taken alloHSCT showed 36% of 3-year OS compared to 17% of 3-year OS for the patients who received autoHSCT 55. In a cohort study including 267 Ph+ ALL patients, 28% of the patients underwent alloHSCT in first complete remission resulted in 44% 5-year OS after matched transplant and 19% after chemotherapy. These results confirmed that alloHSCT is more favored over chemotherapy alone 30. The need for alloHSCT has been questioned after TKIs became the prior treatment agent with much higher effectiveness against Ph+ ALL.

In the GRAAPH-2005 study, after patients were given imatinib with hyper-CVAD or steroids; the ones who had an available donor received alloHSCT after CR1. There were no detectable differences in RFS and OS rates between patients who received alloHSCT or autoHSCT 31. Recently by using ponatinib and hyper-CVAD in the frontline for Ph+ ALL patients, more patients achieved molecular remission independently from whether they have undergone alloHSCT or not. These results showed the alloHSCT can be expendable in CR1 since it did not serve as a predictive factor for OS 56.

1.4. Resistance to Tyrosine Kinase Inhibitors

There has been a consensus about how imatinib and other generation TKIs have moved Ph+ ALL treatment to a new era. Although the prognosis for CML patients have
improved, it is estimated that one third of these patients that are on the first-line therapy will develop resistance to imatinib and, thus, eventually require other therapies. TKI resistance mechanisms can be grouped into two, BCR/ABL dependent and independent mechanisms. BCR/ABL dependent mechanisms includes BCR/ABL amplification or mutations in the TKI binding site, which is most commonly researched in clinical studies. TKI resistance can also be classified based on how the resistance occurs as such primary or intrinsic and secondary or acquired resistance. In intrinsic resistance, the resistance mechanism already exists in the patients and therefore these patients do not respond to TKI treatment at all. On the other hand, acquired resistance is developed by time as the patient is exposed to long-term TKI treatment. Therefore, despite there is an initial response detected in patients, the established response is getting lost afterwards. Different TKI resistance mechanisms seen in cancer cells are discussed detailed in the following section.

1.4.1. BCR/ABL Mutations

Most of the resistance (both types) is thought to be caused by mutations in the kinase domain of BCR/ABL protein. In the intrinsic resistance, BCR/ABL is initially mutated in the leukemic blasts, which makes TKIs dysfunctional from the beginning of the treatment. But in the acquired type of resistance, the model suggests that, non-resistant cells are eliminated during the first round of TKI treatment, which presents a survival advantage for the resistant clones. In many studies, it has been shown that consecutive TKI treatment results in more commonly observed TKI resistance. Interestingly, in a group of patients who received imatinib and dasatinib treatment with no detected remission, newly formed BCR/ABL mutations, which were not detected after imatinib treatment, were observed. These group of patients are able to gain mutations against multiple drugs not just TKIs.

The nature of this type of mutations is to occur at the critical locations where only TKI binding is prevented, however ATP binding and kinase activity is still allowed. Since each TKI bind the BCR/ABL in a specific conformation, resistance profiles differ between different TKIs. Some mutations occur at the active kinase site, which blocks TKI
binding locally, on the other hand, other mutations occur at residues that result in changing the whole 3D structure of the protein. For example, since imatinib and nilotinib can only bind to inactive form of BCR/ABL, imatinib or nilotinib resistant patients usually show destabilization of the inactive conformation of BCR/ABL, which prevents the binding of these TKIs. So far, at least 55 residues that cause imatinib resistance at different levels have been identified.

In a cohort study including 1700 patients that harbor BCR/ABL mutations were investigated. They reported that 11% of the patients were carrying at least 2 mutations in the kinase domain which can be seen as compound or polyclonally. Having multiple mutations in the same BCR/ABL molecule is referred to as compound mutations and makes up the majority of the group by 70%. Polyclonal mutations, on the other hand, refers to the ones having different mutations in different BCR/ABL isoforms. This study also confirmed that, specific and repetitive mutations are observed in different TKI resistance profiles. In total, 30 different mutations were observed including T315I, which is the most commonly detected mutation.

In different studies that investigate BCR/ABL mutations in Ph+ ALL, many point mutations were identified and associated with different TKI resistance. O’Hare et al. showed that M244V and H396 mutations are associated to imatinib resistance but responsive to second generation TKIs. In another study, they showed that dasatinib was able to overcome resistance caused by H396R mutation. Although some newer generation TKIs target BCR/ABL protein that is carrying most of the mutations, there is still need for better coverage in terms of TKI targets.

1.4.2. Gene Amplifications

BCR/ABL gene amplifications are known as the driver mechanism of oncogenic activation. Importantly, studies in the field suggest that gene amplification is the second major TKI resistance mechanisms, following BCR/ABL mutations, seen in the clinics. The long-term exposure to the drug can induce the amplification of the target gene, which might result in an increase in the protein levels of the target gene. As a result, the tolerable amount of the drug becomes insufficient to successfully inhibit the targeted targets.
protein and drug-target interaction is disrupted. This idea was suggested for the first time in a study that showed that the overexpressed oncogenes are located in the extrachromosomal site, thus, causing oncogenic stress, perturbed chromatin organization and unsymmetrical nuclear division. This situation was observed as BCR/ABL amplification in the CML patients who were relapsed after imatinib treatment in which intensification of imatinib was not enough to achieve sufficient response from the patients. Additionally, the same mechanism is confirmed by an in vitro study where continuous exposure to imatinib resulted in BCR/ABL amplification. In a study where Mahon et al. generated imatinib resistant cells; Abl gene amplification was detected in the resistant clones. Similarly, this type of mechanism of resistance was observed in other cases where EGFR or FLT3 was amplified as a result of their inhibitors.

A second type of resistance caused by the amplification of certain genes is through amplification of genes that are in alternative signaling pathways which can compensate the lack of main signaling pathways. An important example for such a mechanism is the amplification of MET gene, which encodes the receptor tyrosine kinase for hepatocyte growth factor in non-small cell lung cancer (NSCLC) patients. In different studies, increased levels of MET gene expression were detected in response to continuous treatment of EGFR inhibitors including gefitinib. As a result, MET amplification caused constitutive receptor activation independently from a ligand that led to activation of downstream pathways. Lately, targeting genes directly by using new gene-editing tools such as CRISPR are studied to prevent effects of gene amplifications in cancer.

### 1.4.3. Genomic Deletions

Genomic deletions are a type of mutations, which can also be described as the loss of a certain part of a DNA sequence or a part of a chromosome. The size of the deleted part in the genome can vary from a single base to a whole chromosome. This mechanism come across as a resistance mechanism against TKIs. In a study, bone marrow samples from CML patients were collected first before the treatment starts and again after relapses were observed; and genome wide comparative genomic hybridization (CGH) was performed. They detected genomic deletions were responsible from 28% of the copy
number alterations in which the genes involved in mitogen-activated protein kinase (MAPK) signaling pathway were found to be the most frequently altered ones 75.

On the other hand, miRNAs, which have a regulatory effect on many genes that are involved in cancer development and progression are among the genes that are most frequently deleted. MiRNAs have the ability of binding complementary sequences of transcribed mRNAs in the genome, which cause those mRNAs to degrade, thus resulting in a lack of the translation of the encoded protein. The proteins that are downregulated by miRNAs can be overexpressed again due to a deletion in the genomic region of certain miRNAs that are involved in those proteins’ regulation 76,77. In the same context, in a recent study, it was shown that miR-21 overexpression was associated with high EGFR activation in NSCLC cell lines and patient samples. They confirmed these results by inhibiting EGFR with AG1478 which resulted in downregulation of miR-2178. Different groups have shown the regulation of resistance by miRNA expressions which is thought to be related to TKI resistance as well 79,80. Indeed, in a study conducted by Nishioka et al. it was reported that downregulation of miR-217, which cause upregulation of DNA methyltransferases (DNTM) expression, was correlated to TKI resistance. To confirm, overexpression of miR-217 inhibited (DNTM) expression by binding of miR-217 to 3’-untranslated region (UTR) of DNTM3A, thus, resulting in the sensitization of TKI-resistant K562 cells to treatment 81. Also in another study, a common genetic deletion polymorphism in B-cell chronic lymphocytic leukemia-lymphoma like 11 gene (BIM) was identified as a cause of resistance to TKI therapy, which was especially correlated to intrinsic resistance 82. Recently, in another study, it was reported that exon 7 deletion in BCR/ABL gene and p.E282Q and p.L298R point mutations were correlated to TKI resistance in CML cases 83. Genomic deletions were identified as a TKI resistance mechanism in Ph+ ALL too. In a cohort study with 97 Ph+ ALL patients, it was reported that deletions in CDKN2A/2B genes caused negative response to TKI 84.

1.4.4. Alterations in Protein Expression

Among various mechanisms of developing resistance against chemotherapeutic drugs, the most common one is for a cell to increase the expression level of the direct
target or secondary target proteins. Although in some cases, alterations in protein expression is placed under the same mechanism as gene amplification; this type of mechanism differs from gene amplification by only accounting for the protein expression levels and not including gene alterations. Same adaptive mechanism is observed in TKI resistance as upregulation of BCR/ABL protein expression levels. A study have shown that nilotinib resistant CML cells have an upregulation in the expression levels of BCR/ABL protein 

On the other hand, epigenetic modifications or environmental stress could also trigger this type of adaptive mechanism. It has been proven that long-term TKI exposure cause a decrease in the blood flow, which results in an increase in the incidence of hypoxic areas. This situation brings the upregulation of HIF-1a protein, which can induce multiple gene expressions such as MET, RTK that will eventually lead to an activation of the key survival pathways including MAPK and PI3K. In another study, hypermethylation in PTEN gene promoter was detected in gefitinib resistant lung cancer cell, this study have shown that when PTEN was induced by exogenous activation, the cells were sensitized back to gefitinib. Another survival-promoting protein Yes-associate protein (YAP) was also shown to be involved in TKI resistance in a study conducted by Lee et al. They showed that an increase in YAP protein levels leads to TKI resistance in lung cancer cells and suggested the usage of YAP inhibitors together with TKI as a treatment strategy.

1.4.5. Activation of Alternative Signaling Pathways

BCR/ABL, a driver protein in leukemogenesis of CML and Ph+ ALL, activates multiple secondary signaling pathways that regulate proliferation, cell cycle regulation, survival etc. Cancer cells can activate those secondary signaling pathways through bypassing BCR/ABL activation or can activate alternative BCR/ABL independent signaling pathways to promote proliferation. The same mechanism is observed in resistance to various TKIs.

Gefitinib targets epidermal growth factor receptor (EGFR) and interrupts the signaling through EGFR. In the case of gefitinib resistance, instead of the signaling through EGFR, the cells activate HGF, MET, MAPK/extracellular signal regulated kinase
(ERK)1/2 and PI3K/Akt signaling cascade as an adaptive resistance mechanism \(^{89}\). On the other hand, insulin-like growth factor-1 (IGFR-1) overexpression is detected as a compensatory mechanism for the lack of EGFR signaling. It was shown that heterodimerization of EGFR and IGFR-1 results in activation of PI3K/Akt and MAPK pathways which eventually leads to resistance to gefitinib \(^{90}\). Some other mechanisms including loss of PTEN or Gab1/Shp2 overexpression by a PI3K-dependent induction were also reported as resistance mechanisms by different studies. Constitutive activation of Akt due to PTEN instability results in cetuximab and/or gefitinib resistance \(^{91}\). In another study, dephosphorylation of Akt, ERK and STAT5 was not achieved by imatinib in imatinib resistant cells while PTEN deactivation was detected \(^{92}\). Also, silencing of PTEN gene was shown to increase EGFR activity by disrupting the ubiquitylation and degradation of the receptor through degradation of newly formed ubiquitin ligase complex \(^{93}\).

In an important study by Quentmeier et al., it was shown that the insensitivity of BCR/ABL positive cell lines to imatinib is due to the activation of BCR/ABL independent PI3K/Akt/mTOR signaling. In a study, some signaling cascades other than PI3K such as ERK, JAK/STAT were inactivated due to imatinib. The inhibition of those pathways individually did not have any effect on cell proliferation. On the other hand, in contrast to imatinib, inhibition of PI3K, PDK1 and mTOR was able to inhibit PI3K/AKT1/mTOR signaling. This suggests that PI3K pathway is constitutively activated through an imatinib-independent mechanism, which may include RAS, CBL or p85 genes, in imatinib resistant cells \(^{94}\).

Another important mechanism for resistance to TKI is the overexpression of genes, which belong to the family of inhibitor of apoptosis. One of the most commonly observed mechanism is overexpression of survivin protein, which is encoded by BIRC5 gene. Survivin works by inhibiting caspase activation that leads to dysregulation of apoptosis. Overexpression of survivin has been associated with chemoresistance by different studies. In a study by Xia et al., survivin overexpression was detected in lapatinib resistant breast cancer cells and confirmed by clinically collected data \(^{95}\). Additionally, survivin was detected at higher levels in the blast crisis and accelerated phases in CML patients, which suggests the involvement of survivin in the progression of CML patients from chronic phase to further aggressive phases \(^{96,97}\). Another study have shown that the level of survivin was correlated to the level of BCR/ABL expression, thus, suggesting that survivin may be regulated by BCR/ABL kinase. This mechanism, then, was
confirmed by Carter et al., where survivin expression was targeted by BCR/ABL and MAPK at mRNA and protein levels in a patient during the blast crisis phase. Additionally, inhibition of survivin was shown to increase imatinib sensitivity and overcome resistance in CML cells 98.

### 1.4.6. Alterations in Drug Influx/Efflux Mechanisms

Multiple mechanisms have been identified that decrease the intracellular concentration of a chemotherapeutic drug, which results in treatment failure. One of these culprits is the alterations in drug influx/efflux mechanism. The mechanism is represented by either an increase in the expression of efflux pumps or a decrease in the levels of influx pumps. The major efflux pumps are listed as ATP-binding cassette (ABCB1)/P-glycoprotein (P-gp) and ABCG2/breast-cancer-related protein (BCRP) whereas the most commonly studied influx pump is organic cation transporter-1 (Oct-1) 99. Although some TKIs have been detected to inhibit ABC transporter activities by binding to their ATP-binding sites, this type of mechanism is still observed in the cases of TKI resistance. TKIs such as cediranib, lapatinib and sunitinib have been reported to reverse resistance through transporter proteins by inhibiting the action of ABC proteins. Herewith, using those inhibitors have been suggested for combinational therapies in cancer treatment 100,101.

Different studies have reported the involvement of efflux pumps in chemotherapy resistance. ABCB1 was shown to play different roles in chemoresistance in various leukemias. In a study by Mahon et al., it was shown that imatinib resistant cells overexpressed P-gp, which was later confirmed by different studies where they sensitized cells to imatinib through the inhibition of P-gp pump activities by using different inhibitors or RNAi 102–104. Although second generation TKIs were able to overcome imatinib resistance in some cases, P-gp was found to contribute to nilotinib resistance as well 85. Importantly, dasatinib and sunitinib have been shown to be substrates of ABCB1 and -2 105,106. Gefitinib on the other hand, has been shown to inhibit ABCG2 activity 107.

Clinical studies have confirmed the association between efflux proteins and chemotherapy resistance. In a cohort study, it was reported that the response to daunorubicin and cytarabine was correlated with ABCB1 expression and activity levels
in CML patients who are mainly in the blast crisis phase. This data showed that the BCR/ABL level is not the only determining factor for prognosis of the patients in blast crisis and multiple factors should be considered for the risk of resistance development. In another study, they observed high levels of ABCB1 expression in each phases of the disease in CML patients but detected that ABCB1 was more involved than multidrug-resistant protein 1 (MRP1) in CML patients who are in the blast crisis phase.

BCRP2 on the other hand, is another efflux pump, which was shown to be involved in drug resistance in cancer. It is encoded by the gene ABCG2 and has been studied in different leukemias. In a study by Nakanishi et al. a cell line, which was resistant to substrates of ABCG2 and imatinib, was able to be sensitized to imatinib by inhibiting ABCG2. Interestingly, ABCG2 related imatinib resistance was reduced by inhibition of BCR/ABL, thus, suggesting the regulation of ABCG2 by BCR/ABL. A single nucleotide polymorphism seen in ABCG2 gene is responsible for the expression level, ATPase activity and drug transport functions of ABCG2. Daily concentration of imatinib could be determined by looking at the polymorphism that the patients harbor, such as having 421 C/C genotype requires higher concentrations whereas 421 C/A or 421 A/A genotype could receive lower concentrations of imatinib. So a genetic screening for ABCG2 gene could be a useful approach to make dosage decisions for the patients.

1.5. BCR/ABL Signaling Mechanisms

As of 1990, BCR/ABL has been identified as the driver oncogene in the progression of CML and Ph+ ALL. Since then, the mechanism and the working principle of BCR/ABL has been extensively studied and well-understood. Two key motifs within BCR site has been determined to be certainly required for leukemia formation. One of the motifs is located at the N-terminus of the protein and responsible for heterodimerization, phosphorylation and activation, which leads to the activation of downstream signaling pathways. The second motif is the binding site for GRB2 adapter protein and found to be stoichiometrically phosphorylated in leukemic cells. GRB2 together with GAB2 activates PI3K pathway, which contributes to survival and proliferation of leukemic cells. In a study, GAB2 was suggested as the strongest
contributor to BCR/ABL independent TKI resistance since it was amplifying the signal coming from BCR/ABL towards targets such as PI3K and RAS pathways 115.

One of the major pathways that is activated through BCR/ABL signaling is PI3K/AKT/mTOR pathway, which was activated through GAB2. The PI3K signaling has been shown to have important roles in BCR/ABL driven leukemogenesis 116. In recent studies, it was reported that TGF-β in addition to AKT signaling play important roles in leukemia progression. Naka et al. showed that AKT, nuclear FOXO3a and SMAD2/3 are inactivated in the progenitor CML cells in mice while it was known that BCR/ABL activates PI3K, which causes phosphorylation and enables the transport of FOXO3a to the nucleus 117. On the other hand, mTOR, which is located downstream to PI3K/AKT pathway, is a serine/threonine kinase and functions together with two complexes mTORC1 and -2. It was also demonstrated that both of the TORC proteins are important in the survival and proliferation mechanisms in BCR/ABL positive cells 118. In a study by Mohi et al., using the mTOR inhibitor rapamycin in combination with imatinib has been found to prolong survival in CML models as well as being effective in resistance caused by BCR/ABL mutations 119. In other studies including patient samples and BCR/ABL positive cell lines, mTORC1/2 inhibitors showed inhibitory effects on proliferation 120,121.

AMP-activated protein kinase (AMPK) pathway is another pathway that regulates mTOR signaling in a direct and an independent manner. After activation, AMPK activates TSC complex by phosphorylation, thus, resulting in the suppression of Rheb activity, which is a regulator of mTOR activation 122. In an important study by Puissant et al., using resveratrol, which is a natural flavonoid found in red grapes, showed inhibitory effects on cell proliferation of imatinib sensitive and resistant CML cells even the ones carrying T315I mutation, through the modulation of AMPK 123. The fact that AMPK induction causes mTOR inhibition independent of the resistance status, therefore, suggesting the idea of using AMPK activators in BCR/ABL positive leukemias 124.

Phosphorylation of Tyr177 in BCR site regulates the SH2 dependent binding of GRB2 to BCR/ABL protein. Similar to GRB2, son of sevenless (SOS), which is an effector of GRB2, regulates RAS activation.

Additionally, it has been reported that BCR/ABL can activate ERK by the signaling through RAS/RAF/MEK/ERK pathway 125,126. ERK has been found to be constitutively active in BCR/ABL transformed stem cells. Importantly, ERK has been shown to be involved in imatinib resistance as well 120.
The role of JNK pathway, which is another major signaling pathway in the cells, has not been fully elucidated in leukemia. Whereas some studies suggested the pro-apoptotic roles of JNK in response to different agents in BCR/ABL positive cells, some others have shown that BCR/ABL induced leukemia promoting features of JNK. Mancini et al. reported that BCR/ABL activity inhibits JNK activation whereas imatinib causes re-phosphorylation of JNK, thus, resulting in activation of apoptosis. Moreover, resveratrol treatment has been shown to induce autophagy in CML cells through JNK dependent accumulation of p62. All these studies exhibited the controversial roles of JNK pathway in BCR/ABL induced leukemogenesis and more needs to be done to clarify its exact role.

Phosphorylation and constitutive activation of STAT5 has been identified in different hematological cancers including BCR/ABL positive leukemias. Additionally, STAT5 activation has been shown to contribute to growth and viability in BCR/ABL transformed cells. In other studies, silencing STAT5 by siRNA inhibited colony formation in CML progenitor cells. Together with the roles of STAT5 in a BCR/ABL dependent manner, JAK kinases have been found to be activated in BCR/ABL positive cells. JAK2 can form a complex with BCR/ABL through C-terminus of BCR/ABL and is involved in the activation of SRC kinase LYN. However, JAK2 or the binding site on BCR/ABL are not found to be required for the induction of leukemia. On the other hand, the involvement of JAK2 signaling in the TKI resistance has been suggested however there is a need for it to be further investigated together with the need of further investigation.

Hedgehog (Hh) pathway has been identified as one of the key signaling pathways that are essential for stem cells throughout differentiation. The signaling through this pathway finalizes with translocation of GLI transcription factors into the nucleus, which results in cell proliferation, survival through mediation of the expression of Cyclin D, c-myc and BCL2 genes. The involvement of Hh pathway in the CML progression has been identified by Dierks et al. where they showed an overexpression of SMO, GLI1 and PTCH1 in BCR/ABL transformed cells in mice. Additionally, this data was confirmed with data from patient samples who are either in chronic or blast crisis phase. It was also reported that Smo deficient mice showed downregulation of BCR/ABL levels and the incidence of CML-like leukemia. Smo antagonist cyclopamine treatment has been shown to prolong survival in addition to a decrease in the CML stem cells. In a promising
clinical study, another SMO antagonist P-04449913 (Pfizer) showed a dramatic elimination of stem cells in different leukemias including CML.\textsuperscript{136}

Last but not least, Wnt/β-catenin pathway works as another downstream pathway of BCR/ABL signaling. Its association with BCR/ABL has been identified for the first time in a study where they detected an accumulation of nuclear β-catenin in granulocyte progenitor cells in CML patients who are in blast crisis.\textsuperscript{137} The elevated levels of β-catenin have been linked to self-renewal features of malign progenitor cells. Additionally, the role of Wnt pathway in CML progression has been reported in other studies in which various target genes of Wnt including c-myc, cadherin, MDI1, FZD2, pricle 1 and ROK13A has been found to be overexpressed during accelerated phase and blast crisis in CML patients.\textsuperscript{138} In a recent study, it was suggested that β-catenin signaling was required in CML stem cells but not in normal hematopoietic stem cells suggesting β-catenin to be a potential target in earlier phases of the disease.\textsuperscript{139}

### 1.6. Bioactive Sphingolipids

Bioactive sphingolipids are a major class of lipids that have structural roles in membrane formation in addition to their involvement in various cellular mechanisms including growth, proliferation, cell cycle regulation, signal transduction, cell-cell interactions, recognition, etc. Sphingolipids were isolated for the first time from the brain tissue by J. L. W. Thudichum who named them as “sphingosin”, inspired from the Greek mythical creature, the Sphinx.\textsuperscript{140} Further studies have clarified the chemical structures and biological roles of sphingolipids. Sphingosine structurally is the major sphingoid base and found in all sphingolipids, which is the distinguishing characteristics of sphingolipids among all lipids. Sphingolipid metabolism is mainly found in eukaryotes but exceptionally it is found in the Sphingomonas bacteria. The sphingolipid pathway has a metabolic entry point which starts with the enzyme serine palmitoyl transferase and has an exit point where sphingosine-1-phosphate (S1P) lyase is produced. Multiple pathways together with complex crosstalks are involved in the sphingolipid metabolism.\textsuperscript{140}

Ceramide, being the central hub of the sphingolipid metabolism, is located at the central position in the sphingolipid metabolism. As a first step in the sphingolipid de novo
synthesis pathway serine palmitoyl transferase (SPT) catalyzes the reaction for the condensation of serine and palmitate to form 3-keto-dihydrosphingosine. A series of reactions eventually ends up with the production of ceramide followed by production of other sphingolipids \(^{141,142}\). In the first downstream pathway, ceramide is phosphorylated and ceramide-1-phosphate (C1P) is produced by the action of the enzyme ceramide kinase (CK); or sphingomyelin (SM) can be produced by addition of a phosphocholine headgroup taken from phosphatidylcholine (PC) to ceramide which is catalyzed by sphingomyelin syntheses (SMS) \(^{143–145}\).

On the other hand, ceramide can be converted into glucosylceramide and galactosylceramide by receiving a glucose molecule through the action of glucosylceramide synthase (GCS) and therefore complex sphingolipids are produced. All those reactions that are converting ceramide to other sphingolipids are reversible. For example; the breakdown of glucosylceramide and galactosylceramide back to ceramide is catalyzed by a hydrolyzing reaction through β-glucosidases and galactosidases. Also, SM is converted back to ceramide through the action of several sphingomyelinases (SMase) including acid SMase, neutral SMase and alkaline SMase \(^{146–148}\).

Figure 1.2. Sphingolipid synthesis and metabolism.
Ceramide, itself can be broken down and form sphingosine by multiple ceramidases. Here, sphingosine may go into “salvage pathway” and recycled back into sphingolipid pathway or can be phosphorylated by the enzyme sphingosine kinases (SK-1 and SK-2) and produce sphingosine-1-phosphate (S1P). Again, the reaction can be reversed by S1P phosphatases. Moreover, S1P is cleaved by S1P lyase and forms etanolamine phosphate and hexadecenal. As the final recycling step, etanolamine phosphate and hexadecenal can be reduced to palmitate and as mentioned, can be used in the first step of sphingolipid de novo pathway. Sphingolipids exhibit a complex and interconnected pathway, which orchestrate cellular reactions through biochemical interactions. In a cell, when SMases are activated, ceramide is produced as a response however, this ceramide might be converted to C1P, S1P or glucosylceramide through subsequent action of the responsible enzymes such as ceramidase, CK, SK, GCS or SMS. On the other hand, relative levels of these sphingolipids might create a response at higher levels than expected. As an example; SM usually abounds in the cells, which makes small changes in SM to reflect severe changes on ceramide levels. Additionally, the concentration of ceramide in the cells is an order of magnitude higher than those of sphingosine, which results in the same situation where small changes in ceramide levels can reflect as double amount of changes in sphingosine levels. Similarly, a small amount of phosphorylation in the sphingosine (2-3%) might result in 2-3-fold changes in the S1P levels. Therefore, when an enzyme in the sphingolipid metabolism responds to a change in the cells, there might be other signaling effectors other than the direct product of this enzyme. Consequently, determining the actual sphingolipid that is mediating the signal carry importance in these type of processes in the cells.

The signaling and regulatory effects of sphingolipids are in part due to subcellular localization of sphingolipids. For example, neutral SMase 2 is usually found in the inner leaflet of the plasma membrane while acid SMase is located to the endolysosomal pathway but can be relocated to the outer leaflet of the plasma membrane. In addition, SK-1 and SK-2 usually take action on the sphingosine substrates that resides in the membranes, which results in the translocation of these enzymes to the membranes from their cytosolic compartment. Therefore, SK enzymes are known as having various subcellular localizations, which could determine their final functions.

Bioactive sphingolipids can be divided into three subgroups based on their biophysical properties as follows: the ones carrying ionic charges and neutral pH; the ones carrying neutral hydrophobic molecules and the ones possessing single-chain lipids.
C1P and phosphatidylinositol-3-phosphate belong to the first group and they usually are unable to move from their own compartments and unable to flip across bilayer membranes. Ceramide and diacylglycerol (DAG) on the other hand, are under the second group and are stable at their compartment, but able to flip across membranes. S1P and derivatives of sphingosine falls under third group and are composed of a single chain, in addition to that, they have the ability to dissolve in aqueous environment and flip between membranes.

1.6.1. Ceramide Metabolism and Signaling

The structure of ceramide is formed of sphingosine composed of an amine linked fatty acid chain that varies in length from C14 to C26. It has been indicated that ceramides having different fatty-acid chain length are responsible for different functions in the cells. Therefore, ceramide synthase (CerS) genes carry importance in the cell fate. CerS genes were first identified as longevity assurance gene (LAG1) due to their roles in longevity/life-span in Saccharomyces cerevisiae. Afterwards, the mouse homologue LASS1 was discovered and identified to be responsible for the synthesis of C18-ceramide. Other classes of CerS genes were identified later on and named as LASS proteins (LASS1-6), which were then renamed as ceramide synthases 1-6 (CerS1-6). CerS proteins reside in the endoplasmic reticulum (ER) membrane and they contain a TLC (TRAM-Lag1p-CLN8) domain. This domain is crucial for the catalytic activity of CerS and required for the synthesis of ceramides. In addition, all CerS except for CerS1 contain another domain, which is the homeobox transcription factor (HOX) that is known to be responsible for the enzymatic activity, however, the physiological roles of this domain remain unclear.

As mentioned before, each CerS is responsible for the synthesis of ceramides with different fatty-acid chain lengths. It has been identified that CerS1 catalyzes the synthesis of C18-ceramide whereas CerS5-6 is responsible for the generation of mainly C16-ceramide in addition to C12- and C14-ceramides. CerS2 on the other hand generates long chain ceramides such as C22-, C24- and C26-ceramide. CerS3 was shown to contributes...
to the synthesis of C18- and C24-ceramides whereas CerS4 is responsible for the generation of C18- and C20-ceramides.

*De novo* synthesis of ceramide occurs in the ER and the reaction starts with a key enzyme SPT, which catalyzes the condensation of serine and palmitate to form 3-keto-dihydrosphingosine. Then, 3-keto-dihydrosphingosine is reduced to dihydrosphingosine by the enzyme 3-ketosphingosine reductase. The formed dihydrosphingosine is converted to dihydroceramide by the family of CerS; followed by the final step to produce ceramide catalyzed by dihydroceramide desaturase (DEGS). Newly generated ceramides are transported to Golgi apparatus by two different mechanism; either by vesicular trafficking or with the help of ceramide transfer protein (CERT). Further metabolization of ceramide to generate other complex sphingolipids occurs in Golgi apparatus.

![Figure 1.3. Major sphingolipids and their involvement into cellular mechanisms.](image)

Different studies have revealed the involvement of CerS genes and ceramides in cancer progression. In a study by Karahatay et al. although C18-ceramide levels were detected as low; C16-ceramide levels were detected as dramatically high in head and neck squamous cell carcinoma (HNSCC) patients compared to their own health tissues. The levels of C16- and C18-ceramides were associated with the expression levels of CerS1.
and -6 genes. In a recent study conducted with the participation of 44 patients, they reported that ceramide levels were elevated in breast cancer patients. Moreover, they showed that the levels of ceramides are inversely correlated with the aggressiveness of the cancer.

Ceramide is involved in different cellular functions in cancer such as growth inhibition, apoptosis or senescence. The regulation of these biological mechanisms occurs through lipid-protein interactions. In most of the cases, direct targets of ceramide are either protein phosphatases or kinases, which control the activation of important signaling pathways that promote and maintain cancer progression. Akt, protein kinase C (PKC) and MAPK pathways are identified as downstream targets of ceramide. The first identified ceramide-associated regulatory proteins are phosphatase-1 and -2 (PP1 and PP2A), which are also known as Ceramide Activated Protein Phosphatases (CAPP). The activation of CAPPs induces the activation of apoptotic Bcl-2 proteins, cell cycle regulatory proteins cyclin dependent kinases (CDK) and the tumor suppressor protein Rb. Additionally, ceramide activates cathepsin D, which is a ceramide binding protein that results in activation of apoptosis. Similar to cathepsin D activation, ceramide also activates protein kinase zeta (PKC-zeta) that induces the formation of a pro-apoptotic complex composed of PKC-zeta and PAR-4 (prostate apoptotic response-4) in stem cells that undergo differentiation process. Moreover, the activation of PKC-zeta has been shown to inactivate Akt, which results in growth arrest in vascular muscle cells. One of the best characterized ceramide-binding protein, CERT, has been shown to be involved in the sensitivity of cancer cells against chemotherapeutic agents. Therefore, it was suggested that the changes in sphingolipid metabolism regulated by CERT might be an important factor in the survival fate of cancer cells.

1.6.2. Antiproliferative Roles of Ceramide

The predominant function of ceramide is to induce apoptosis in cancerous cells. Apoptosis is a process, which can be triggered by different factors and orchestrated by multiple signaling pathways. The role of ceramide in apoptosis has been suggested by different studies where ceramide production was shown to be regulated by the apoptosis-
inducing factors such as stress, different signals, chemotherapeutic drugs etc. Moreover, many different studies in the literature showed that increasing the endogenous level of ceramides by using different inhibitors of sphingolipid pathway's enzymes results in apoptosis in cancer cells 162,173–178. It was also reported that exogenous treatment with ceramide induces apoptosis in different cancers including leukemia.

Obeid et al. for the first time, identified the pro-apoptotic function of ceramide by exposing cells to C2-ceramide, which is a synthetic ceramide analog N-acetylsphingosine, This resulted in DNA fragmentation, which is characteristic response for apoptotic cells 176. Similarly, it was shown that C6-ceramide induced apoptosis through inhibition of Bcl-2 179. Since then, the role of ceramide as a secondary lipid messenger in apoptotic signaling pathway has been investigated by many studies.

The apoptotic roles of ceramide have been studied in leukemia. In different studies, exogenous treatment with C2- and C6-ceramide has been shown to induce apoptosis in K562, a CML cell line 180,181. The apoptotic function of C6-ceramide has been shown to be associated with caspase-8 and JNK signaling in K562 cells 180. Moreover, different delivery methods of ceramide such as through nanocarriers have been identified to inhibit large granular lymphocytic leukemia (LGL) in mice models. Liu et al. reported the apoptotic action of ceramide was through downregulation of surviving, which is an anti-apoptotic protein 182.

The effect of exogenous ceramide treatment is thought to be through its resembling action of intracellularly induced ceramide generation. Exogenous ceramide was shown to induce the expression of CerS genes, thus, leading to the generation of endogenous ceramide 183. Notably, the cellular functions of ceramide vary by the length of fatty-acid chain. In a study where C16-ceramide was detected as low and C18-ceramide as high, suggesting the pro-apoptotic role of C18-ceramide but not C16-ceramide in HNSCC patients 164,184. In another study, overexpression of CerS6 was shown to induce the growth of HNSCC cells whereas the production of C18-ceramide through CerS1 overexpression inhibited the proliferation of these cells 185.

Another well characterized function of ceramide is to induce cell cycle arrest especially at G0/G1 phase. This action of ceramide is associated to the activation of the tumor suppressor protein retinoblastoma (Rb). Ceramide has been reported to inhibit CDK2 through activation of phosphatase whereas showing no detectable effect on CDK4 186,187. The growth inhibitory effect of ceramide has been shown by an in vivo study where using ceramide coated catheters caused growth arrest in vascular muscle cells. Later on,
the mechanism has been shown to be through inhibition of Akt by ceramide, which was regulated by PKC-zeta activation\textsuperscript{188,189}.

In addition to ceramide's role in activation of apoptosis and its growth inhibitory effects, it is also capable of inducing senescence. This latter role of ceramides was suggested for the first time by Veneable et al. where they showed an increased level of ceramides in human fibroblasts that were undergoing senescence\textsuperscript{190}. In the same study, senescence related morphological and biochemical changes including activation of Rb and alterations in CDKs were detected in response to ceramide treatment. Senescence is known to be regulated by alterations in telomere length through the activation of telomerase. Telomerase is identified as a down-stream targets of ceramide, therefore, suggesting a relation between aging/senescence and ceramide. Ceramide is known to regulate telomerase activation either by dysregulation of c-myc, which results in the inactivation of hTERT promoter or the recruitment of Sp3/HDAC1 complex into hTERT to promote its repression\textsuperscript{191,192}. Additionally, shortening of telomeres through an independent mechanism from telomerase was shown to be regulated by ceramide with an action through the telomere binding function of glyceraldehydes-3-phosphate dehydrogenase (GAPDH)\textsuperscript{193}.

1.6.3. Bioactive Sphingolipids in Drug Resistance in Cancer

As mentioned and detailed previously, drug resistance against chemotherapeutic drugs is the main obstacle in cancer therapy. The relationship between cancer drug resistance and sphingolipid metabolism has been reported in various studies. Therefore, targeting sphingolipids as an approach against drug resistance has been suggested and applied in various studies involving different type of cancers\textsuperscript{194–196}.

The most common mechanism of resistance through sphingolipids is the alteration of ceramide accumulation in the cells. Most of the generated ceramide is metabolized into glucosylceramides by overactivation of GCS in some cancers. This action was identified to contribute to development of drug resistance including many different cancers, especially breast cancer\textsuperscript{195,197}. The action of GCS is known to occur through multiple mechanisms including an action through P-gp (drug transporter protein); decreasing the
concentration of C18-ceramide and causing accumulation of different glycosylceramide species. The link between GCS and MDR has been implicated by different studies. It was shown that silencing GCS by siRNA transfection resulted in the inhibition of MDR1 expression, which leads to the reversal of drug resistance \(^{198,199}\).

Moreover, a P-gp inhibitor has been shown to inhibit GCS and cause a decrease in glucosylceramide levels \(^{198}\). The effect of GCS on drug resistance has been addressed in other cancers including colon cancer, head and neck carcinoma, melanoma and leukemia. Increased activity of GCS and SMS together with lower ceramide levels were detected in chemotherapy sensitive AML patients compared to others. In an \textit{in vitro} study, overexpression of GCS caused doxorubicin resistance in HL-60, an AML cell line. Additionally, increased level of GCS was detected in resistant K562 cells in which GCS inhibition sensitized K562 cells to Adriamycin \(^{200,201}\).

Another sphingolipid family enzyme ceramidase is classified into acid, neutral and alkaline ceramidase based on their enzymatic activity in different environments. Since it is able to breakdown ceramide to generate sphingosine and followed by production of S1P, cells use this mechanism to alter ceramide levels as a strategy for drug resistance \(^{202}\). In a prostate cancer cell line, DU145, elevated expression levels of acid ceramidase showed increased resistance to various agents including doxorubicin, cisplatin, etoposide and gemcitabine, whereas inhibition of ceramidase sensitized the cells to those agents \(^{203}\). Acid ceramidase overexpression was identified in resistance to TNF-\(\alpha\) induced apoptosis in fibrosarcoma cell line, L929, in addition to the reversal of resistance by exogenous ceramide or an acid ceramidase inhibitor N-oleoylethanolamine treatment \(^{204}\). Although more studies need to be done in order to get an insight into the roles of ceramidases in chemoresistance, these pioneering studies revealed ceramidases as a potential target to overcome drug resistance in cancer.

Sphingosine kinase-1 and -2 has been widely studied in the literature and the roles of SK-1 and -2 enzymes in different cellular mechanisms including drug resistance have been addressed almost completely in various cancers. The action mechanism of SK could be through two different but interrelating mechanism, one of which is preventing the accumulation of ceramide and the other one is the induction of S1P generation \(^{205,206}\). Overexpression of SK-1 has been detected in different cancers resistant to different chemotherapeutic drugs.

In CML, SK-1 activity was increased by BCR/ABL through an antiapoptotic protein Mcl-1 while imatinib has been detected to inhibit SK-1 activity \(^{207}\).
Overexpression of SK-1 was detected in doxorubicin resistant myelodysplastic syndromes and acute leukemia cells where the resistance could be reversed by silencing SK-1 by siRNA.

In some solid tumors such as ovarian cancer, resistance to 4-HPR (N-(4-hydroxyphenyl)retinamide) is mediated by SK-1. Moreover, resistance to camptothecin has been linked to high SK-1 activity in a prostate cancer cell line PC3. In addition, SK-1 and -2 was found to contribute to oxaliplatin resistance in a colon cancer cell line, RKO, in which silencing them were reported to reverse oxaliplatin resistance.

In general, from the discussed studies, the literature linking drug resistance and sphingolipids have been mostly focused on the actions of SK-1,-2 and GCS and their products.

1.6.4. Targeting Sphingolipid Signaling in Cancer Therapy

Recent studies have suggested that the targeting of sphingolipid mechanism is a new promising approach in cancer treatment. The strategy with sphingolipids is mainly to accumulate intracellular levels of ceramide to promote cell death in cancer cells. In addition to the aim of accumulating intracellular ceramide, decreasing the levels of pro-survival sphingolipids such as S1P serves as another important approach to battle cancer.

Some chemotherapeutic agents have been shown to increase intracellular ceramide levels through induction of de novo synthesis pathway. Different studies showed either SMase or de novo pathway activation by daunorubicin, fludarabine, etopsine and gemcitabine. On the other hand, targeting ceramide catabolizing/converting enzymes, which results in the accumulation of ceramide has been suggested as a mechanism to induce cell death in different cancers.

Combining the standard chemotherapeutic agents with sphingolipid enzymes has been suggested to be used in cancer treatment. In an in vivo study by Modrak et al. combination of gemcitabine with sphingomyelin resulted in the inhibition of tumor growth synergistically, in pancreatic cancer cells. In another study, SM treatment was detected to cause an increase in cell membrane permeability, which resulted in increased
levels of cellular uptake of doxorubicin, thus leading to an enhanced therapeutic effects of doxorubicin in various cancer cell lines\textsuperscript{215,216}.

Another major strategy in cancer treatment involving sphingolipids is to downregulate S1P levels by blocking the action of SK enzymes. Various \textit{in vitro} and \textit{in vivo} studies reported the anti-proliferative effects of SK1 inhibitors in different cancers. Since S1P can work through two different mechanism: by staying intracellular and directly activating downstream targets, or by moving outside of the cells and binding its own membrane receptors (sphingosine-1-phosphate receptor-1-5 -S1PRs-) and activating G-protein coupled receptor signaling. To this end, the studies showed inhibition of sphingosine-1-phosphate receptors (S1PRs) have been shown to inhibit cell growth \textsuperscript{206}.

Different inhibitors of sphingolipid pathway have been shown to induce accumulation of ceramide by blocking the reactions that convert ceramide to complex sphingolipids. For instance, an acid CDase inhibitor B13, caused the inhibition of tumor growth through the accumulation of ceramide in colon cancer and prostate cancer mouse models \textsuperscript{217,218}. Similarly, inhibition of SMS, which has been shown to increase ceramide accumulation, caused inhibition of tumor growth in multiple types of cancers \textsuperscript{219,220}.

In addition to increasing ceramide levels, increase in dihydroceramide levels has come along as a treatment strategy, which was shown by various studies. Treatment with $\gamma$-tocopherol (a dietary form of vitamin E), induced apoptosis by causing an accumulation in dihydroceramides \textsuperscript{221}. Interestingly, fenretinide had been thought to induce ceramide generation for a long time until different groups have reported the increase dihydroceramide levels due to dysregulation of DES by fenretinide treatment \textsuperscript{222,223}.

Targeting sphingolipids as a strategy to overcome chemoresistance has been widely studied in different cancers. To this end, GCS inhibitors have been widely used in cancer treatment thanks to their action through MDR proteins as previously described in section 1.6.3. Combination of GCS inhibitor with MDR inhibitors induced cell death in different solid tumor cell lines including melanoma, prostate, breast, colon and pancreatic cancers \textsuperscript{224}.

Additionally, SK-1 inhibitor is used to overcome MDR-associated gemcitabine resistance in acute myeloid leukemia (AML) in addition to CML cell lines and patient samples \textsuperscript{207,225}. Sphingosine, which is one of the sphingolipid breakdown products, induced apoptosis in Adriamycin resistant cells \textsuperscript{226}. Also, pharmacological and genetic inhibition of acid ceramidase restored sensitivity to daunorubicin in hepatoma cells \textsuperscript{203}.  

All in all, these studies show that targeting the sphingolipid pathway to be a promising strategy in cancer treatment in terms of both inhibiting tumor growth and overcoming resistance to chemotherapeutics in different cancers including leukemia. The studies aimed to increase the levels of an apoptotic sphingolipid ceramide which serves as an important regulator in cancer progression. Additionally, altering ceramide metabolism by inhibiting the enzymes involved in the sphingolipid pathway in order to inhibit the production of complex sphingolipids showed promising results.

1.6.5. Targeting Sphingolipid Metabolism for the Treatment of Hematological Malignancies

So far, the importance and potential benefits of targeting sphingolipids have been evaluated for the treatment of different cancers including leukemia and solid tumors. Here, the potential effect of targeting sphingolipid metabolism will be discussed from the perspective of BCR/ABL positive hematological cancers including CML and Ph+ ALL.

Several studies suggested that the usage of ceramide modulating agents in combination with BCR/ABL inhibitors provides an effective approach to increase the efficacy of TKI treatment in BCR/ABL positive hematological malignancies. Similar to previously described strategy, inducing the accumulation of ceramide by the application of a GCS inhibitor, PDMP, showed apoptotic effects and restored sensitivity to imatinib and nilotinib in T315I mutated CML cells 227. In a previous study by our group, imatinib treatment induced ceramide generation, especially C18-ceramide, in imatinib sensitive but not in resistant K562 cells, thus, suggesting a potential involvement of CerS1. After examining the role of CerS1 by using siRNA, it was reported that CerS1 (through C18-ceramide generation), not fully but partially, is involved to imatinib induced cell death. In the same study, imatinib resistant K562 cells was found to have elevated SK-1 levels together with increased S1P levels, compared to their parental imatinib sensitive cells, therefore suggesting a potential role of SK-1 in imatinib resistance in CML for the first time in the literature. It was reported that, overexpression of SK-1 in sensitive CML cells was shown to gain resistance against imatinib whereas suppressing SK-1 re-sensitized cells to imatinib 228.
Later on, the mechanism was investigated by Li et al. and reported that the BCR/ABL regulated SK-1 activity was through MAPK, PI3K and JAK2 signaling through a positive feedback loop. The mechanism between SK-1 and BCR/ABL was shown to be via suppression PP2A-mediated dephosphorylation and degradation of BCR/ABL through S1P receptor 2 (S1PR2). In the same study, imatinib resistant K562 cells and patient samples carrying T315 mutation were sensitized to imatinib by targeting S1P/S1PR2 signaling. Notably, higher expression levels of SK-1 and S1PR2 was detected in the patients with T315I mutation suggesting a potential link between BCR/ABL mutational status and SK-1 levels in CML patients.

More studies from our group and other groups reported that BCR/ABL inhibitors such as nilotinib, dasatinib and GFN-2 induced ceramide generation via increasing the expression of CerS genes. Different TKIs has been shown to act through different CerS genes such that; dasatinib was associated with CerS2, -5 and -6 whereas nilotinib was shown to increase CerS5 expression. GCS inhibitor PDMP in combination with nilotinib or dasatinib was shown to have cytotoxic effects on CML cells through accumulation of intracellular ceramide levels. These studies highlighted the interplay between BCR/ABL, ceramides, SK-1, GCS and CerS to feed into pro-survival effects of BCR/ABL in CML. Moreover, these crosslinks put forward the use of sphingolipid inhibitors together with TKIs for the treatment of BCR/ABL positive hematological malignancies.

Ph+ ALL treatment has resided as challenging for a long time as detailed previously in sections 1.2 and 1.3. Previous studies in CML has served as a base to initiate the studies in sphingolipid metabolism and Ph+ ALL. The first study revealed the role of SK in ALL by using an SK-1 and -2 inhibitor, SKI-II in combination with vincristine. SK inhibition caused an accumulation in ceramide levels and even more when applied together with vincristine, which results in a synergistic effect on cell death in primary lymphoblasts. Moreover, in another study they combined only SK-2 inhibitor together with doxorubicin or vincristine, which led to an additive effect suggesting the previously seen synergy that was due to SK-1 inhibition.

After the promising results seen in ALL, the role of SK-1 has been investigated in Ph+ ALL. In the first cohort study by Li et al. they detected an elevated level of SK-1 expression in BCR/ABL positive ALL patients, compared to BCR/ABL negative ones. This study was the first to reveal the potential relationship between BCR/ABL and SK-1, similar to the one addressed in CML. Moreover, in another study it was reported
that combination of SK inhibitors with imatinib showed synergistic cell death in BCR/ABL positive ALL cell lines.  

After addressing the importance of SK-1 in ALL, the increase in the levels of SK-2 and its activation has been identified in ALL patient samples. Furthermore, SK-2 inhibition resulted in dysregulation of histone acetylation of c-Myc promoter, which was identified as a new mechanism of action of SK-2. Decreased levels of c-Myc expression through SK-2 suppression was detected in BCR/ABL transformed ALL cells, thus, resulting in prolonged survival in mice models.

1.7. Aim of the Study

The emerging need of novel strategies for the treatment of Ph+ ALL resulted in seeking new treatment options. Previously described mechanisms implicated rewiring sphingolipid metabolism by using different inhibitors of sphingolipid enzymes especially SK and GCS, therefore revealing novel therapeutic approaches by mainly inducing ceramide accumulation. Previous studies reported the potential role of SK-1 and -2 in Ph+ ALL but the mechanism of SK inhibition from sphingolipid perspective that results in additive effects on cell death has not been clarified.

Additionally, the roles of other sphingolipids especially ceramide in imatinib induced cell death has not been addressed at all by any of these studies. Given the knowledge in the literature and knowing that TKI, especially imatinib resistance has been identified as the most challenging phenomenon in Ph+ ALL treatment, we wanted to investigate the roles of sphingolipids in imatinib induced cell death in the context of Ph+ ALL and reveal the potential link between imatinib resistance and sphingolipids in Ph+ ALL. There is only a limited number of studies in the literature that is discussing and addressing imatinib resistance mechanisms in Ph+ ALL and none of them is from sphingolipid perspective. Therefore, by investigating the involvement of sphingolipids in imatinib resistance, we are also aiming to exploit sphingolipid metabolism to increase sensitivity to imatinib by mimicking the clinical resistance models.

The starting point was to choose an intrinsically more resistant cell line to begin with to mimic intrinsic resistance seen in the patients; then continued with generating a
resistant cell line, which mimicked the acquired resistance condition in patients. We tackled the roles of sphingolipids in imatinib induced cell death in Ph+ ALL in a similar to the manner to what was previously described in CML. Then, we investigated the involvement of each sphingolipids and addressed their contribution to cell death induced by imatinib. Afterward, the roles of sphingolipids in imatinib resistance in Ph+ ALL was evaluated together with determining the sphingolipids that are contributing in imatinib resistance and how they could be rewired to overcome imatinib resistance in Ph+ ALL. Additionally, we investigated the roles of SK, GCS and CerS in imatinib induced changes in Ph+ ALL as referred to in previous studies in both Ph+ ALL and CML.
CHAPTER 2

MATERIALS AND METHODS

2.1. Chemicals and Reagents

Cell culture medium RPMI 1640 was obtained from Thermo Fisher Scientific, Waltham, MA, USA (Gibco) and penicillin streptomycin is from Life Technologies (Gibco). Fetal bovine serum was obtained from Thermo Fisher Scientific, Waltham, MA, USA (Gibco). Imatinib was purchased from Santa Cruz Biotechnology, Dallas, TX, USA; eliglustat tartrate, PF543 and SKI-II were obtained from Sigma Aldrich, St. Louis, MO, USA; myriocin was purchased from Cayman Chemical, Michigan, USA. All the chemicals were dissolved with certain solvents (DMSO or water) and stock solutions were kept at indicated temperature as indicated by the manufacturer.

2.2. Cell Lines and Culture Conditions

Philadelphia chromosome positive human acute lymphoblastic leukemia cell line SUP-B15 was purchased from the American Type Culture Collection (Manassas, VA, USA) and SD-1 was purchased from the German Collection of Microorganisms and Cell Cultures (Leibniz Institute DSMZ, Germany). Philadelphia chromosome negative acute lymphoblastic leukemia cell line CCRF-CEM was purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were maintained in RPMI 1640 media containing 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C and 5% CO2 in a humidified incubator.

Mycoplasma detection was done every month to detect any possible contamination by using MycoAlert™ Mycoplasma Detection Kit (Lonza).
2.3. Thawing Frozen Cells

After receiving the cell lines CCRF-CEM SUP-B15 and SD-1; the cells were thawed in a water bath at 37°C and immediately transferred into 5 ml pre-warmed media for centrifugation. Then, the cells were centrifuged at 800 rpm for 5 min to get rid of the supernatant that contains DMSO. The pellet is resuspended with fresh pre-warmed media and transferred into T25 tissue culture flasks for initial maintenance and later on transferred to T75 flasks for regular maintenance. This process is repeated every 3 months to keep the passage number low to keep the cells in a healthy state.

2.4. Maintenance of CCRF-CEM, SUP-B15 and SD-1 Cell Lines

All the cells in suspension was taken from the tissue culture flasks and transferred into falcon tubes. The clusters were disrupted by gently pipetting the cells. Then, the cells were centrifuged at 600 rpm for 5 min and the pellet was resuspended with fresh media. After counting the cells by using trypan blue dye; SUPB-15 cells were seeded at the density of 0.5x10^6 cells/ml and CCRF-CEM and SD-1 cells were seeded at 0.3x10^6 cells/ml in T75 tissue culture flasks with the final volume of 20-30 ml media.

2.5. Freezing Cells

Cells were frozen at earlier stage of the experiments to store them for using in further studies. Around 20x10^6 cells were collected by centrifugation and the pellet was resuspended with 10 ml of the freezing media containing 20% of FBS and 10% DMSO with RPMI 1640 media. The cells and freezing media were mixed well and 1 ml from cell suspension transferred into each cryogenic vial. The vials are placed into a MRFrosty freezing container (Thermo Scientific) and incubated at -80°C overnight and then stored in liquid nitrogen (-196°C) for longer period.
2.6. Generation of Imatinib Resistant SD-1 Cells

Cells were cultured in the presence of step wise increasing concentrations of imatinib, starting with a concentration of 0.05 μM \(^{228}\). Cells were routinely seeded at 0.3x10\(^6\) cells/ml in growth medium containing imatinib; every 48 h, media and drug were refreshed; once the cells reached the maximum confluency (1x10\(^6\) cells/ml), the cells were diluted back to 0.3x10\(^6\) cells/ml and the concentration of imatinib was doubled. Once cells were able to grow in the presence of 10 μM of imatinib, the drug concentration was kept constant and these cells were named SD-1R and maintained in the same 10μM concentration of imatinib throughout the study.

![Diagram showing the generation of resistant cell line (SD-1R) by clonal selection](image)

Figure 2.1. Generation of resistant cell line (SD-1R) by clonal selection

2.7. Treatment with Imatinib and/or Other Inhibitors

The inhibitors were kept at the certain temperature as suggested by their manufacturer until the day they are used. SD-1R cells were washed in PBS and maintained in drug-free growth medium for 2 passages; at the time of experiments, they
were seeded at 0.3x10⁶ cells/ml and treated side by side with parental SD-1 sensitive cells at the indicated concentrations of imatinib and/or other inhibitors.

2.8. Treatment with Exogenously Added Sphingolipids

Cells were prepared for the treatment as described previously. C6-Ceramide and sphingosine are not directly applied onto the cells with their stock solutions but first diluted in growth media as indicated concentrations and then applied to the cells.

2.9. Determining Cell Viability with Trypan Blue Exclusion Assay

SD-1 and SD-1R cells were seeded at 0.3x10⁶ cells/ml in 3 ml media in a 6-well plate and treated as described in the experiments. At the indicated time point, cells were diluted 1:1 (v/v) with 0.4% Trypan Blue staining solution (Life Technologies) and live (white) and dead (blue) cells were counted using a hemocytometer (Bright-Line Hemocytometer, Hausser Scientific)²³⁷.

2.10. Measuring Cell Proliferation by MTT Assay

Cells were plated at 2x10⁴ cells/well in 200 μl media in a 96-well plate and exposed to drug/inhibitor for the indicated time. Then 20 μl of MTT solution (5 μg/ml) (Sigma Aldrich, St.Louis, MO, USA) was added into the wells and incubated for 3h. The cells were pelleted by centrifugation at 250 g for 10min and the produced formazans were dissolved by adding 150 μl of DMSO into each well. Each sample was mixed thoroughly, and the absorbance was measured at 540nm in a plate reader (Molecular Devices, SpectraMax M5)²³⁸.
2.11. Protein Isolation and Preparation

Approximately 1x10^6 cells were collected by centrifugation and resuspended in 1% SDS to lyse the cells. The samples were boiled in a dry block heater for 10 min and stored at -80°C until they are used.

2.12. Protein Quantification by BCA Assay

Protein concentration was quantified by Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) as described by the manufacturer.

Shortly, 25 μl of each sample and standards of bovine serum albumin (BSA) (Table 2.1) were added into a 96-well plate. 200 μl of working reagent (50:1, Reagent A:B) was added onto each sample and incubated at 37°C for 30 min in dark. The absorbance is measured at 563 nm with using a plate reader. The protein concentrations are calculated based on the standard curve.

Table 2.1. Preparation of diluted bovine serum albumin (BSA) standards.

<table>
<thead>
<tr>
<th>Vial</th>
<th>Volume of Diluent (μl)</th>
<th>Volume and Source of BSA (μl)</th>
<th>Final BSA concentration (μg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0</td>
<td>300 of stock</td>
<td>2000</td>
</tr>
<tr>
<td>2</td>
<td>125</td>
<td>375 of stock</td>
<td>1500</td>
</tr>
<tr>
<td>3</td>
<td>325</td>
<td>325 of stock</td>
<td>1000</td>
</tr>
<tr>
<td>4</td>
<td>175</td>
<td>174 of vial 2 dilution</td>
<td>750</td>
</tr>
<tr>
<td>5</td>
<td>325</td>
<td>325 of vial 3 dilution</td>
<td>500</td>
</tr>
<tr>
<td>6</td>
<td>325</td>
<td>325 of vial 5 dilution</td>
<td>250</td>
</tr>
<tr>
<td>7</td>
<td>325</td>
<td>325 of vial 6 dilution</td>
<td>125</td>
</tr>
<tr>
<td>8</td>
<td>400</td>
<td>100 of vial 7 dilution</td>
<td>25</td>
</tr>
<tr>
<td>9</td>
<td>400</td>
<td>0</td>
<td>0: blank</td>
</tr>
</tbody>
</table>
2.13. Western Blotting

After collecting and quantifying proteins, 20 μg of total proteins were prepared in Laemmli buffer and were separated by Precast Midi 4-20% SDS-Page Gel (Novex, Tris-Glycine, Invitrogen) and blotted onto nitrocellulose membrane (BioRad Laboratories, Hercules, CA, USA). The membrane was blocked with 5% non-fat milk in PBS with 0.1% Tween for 1h at room temperature. The protein levels were detected by using 1:1000 dilution of anti-cleaved caspase-3 (Cell Signaling Technology, Danvers, MA, USA#9661), anti-β-Actin (Cell Signaling Technology, Danvers, MA, USA#4970), anti-GAPDH (Cell Signaling Technology, Danvers, MA, USA#2118), anti-c-ABL (Santa Cruz Biotechnology, Inc. CA, USA #sc-23), anti-BCL2 (Santa Cruz Biotechnology, Inc. CA, USA #sc-7382), anti-BCL-XL (Santa Cruz Biotechnology, Inc. CA, USA #sc-8392) primary antibodies overnight at 4°C in 5% bovine serum albumin (BSA) solution. Then, anti-rabbit or mouse secondary antibodies (1:5000) were used and proteins were visualized by using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, Waltham, MA, USA) on an autoradiography film (Lab Scientific, inc) by an image processor (Konica Minolta SRX-101A).

2.14. RNA Isolation

Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. As a summary; approximately 1x10^6 cells were collected by centrifugation and 350 μl RLT buffer was added onto the samples to disrupt the cells. The same amount of 70% ethanol (350 μl) was added to the lysate and mixed gently. The sample is transferred to an RNeasy spin column with a 2 ml collection tube and centrifuged for 30 s at 10,000 rpm. After the flow through is discarded, 700 μl of Buffer RW1 was added to the column and centrifuged again for 30 s at 10,000 rpm. 80 μl from DNase I incubation mix (10 μl DNase I stock solution + 70 μl Buffer RDD) was directly added to the RNeasy column and incubated at room temperature for 15 min. 500 μl of Buffer RPE was added to the column and centrifuged for 30 s at 10,000 rpm, the
same step was repeated with another centrifuge for 2 min at 10,000 rpm. The spin column was placed in a new 1.5 ml collection tube and 35 μl RNase-free water was added directly to the column. The tubes were centrifuged for 1 min at 10,000 rpm to elute the RNA.

2.15. Quantification of RNA

The amounts of isolated RNAs were quantified by using NanoDrop UV-Vis spectrophotometer (Thermo Scientific™). After blanking the instrument with elution water, 2 μl from each sample was loaded and measured at 260 nm. The amount of RNA in the samples were reported in ng/μl. The purity of RNA was determined by the ratio of 260:280 which is accepted as “pure” if the ratio is around ~2.0 for RNA samples. Also 260:230 ratio was considered as another purity indicator and if around ~2.0 the samples were accepted as “pure”.

2.16. cDNA Synthesis

Equal amounts of total RNA (1μg) were used to reverse transcribe into cDNA. The annealing mixture is prepared as shown in Table 2.2. The mixture is placed in a therocycler and annealed by using the following parameters: 10 min at 70°C, 10 min at 25°C, store at 4°C. In the meantime, the enzyme mix is prepared as shown in Table 2.3 and cDNA is synthesized by using a thermocycler by using the following parameters: 10 min at 25°C, 45 min at 37°C, 45 min at 42°C 15 min at 70°C, store at 4°C.

Table 2.2. Annealing mixture of the cDNA preparation protocol.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Final Concentration</th>
<th>Final amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA</td>
<td>50ng/μl</td>
<td>1μg</td>
</tr>
<tr>
<td>Random hexamers (100ng/μl)</td>
<td>25ng/μl</td>
<td>5 μl</td>
</tr>
<tr>
<td>Water</td>
<td></td>
<td>Add to 20 μl</td>
</tr>
</tbody>
</table>
Table 2.3. The enzyme mix used in cDNA synthesis.

<table>
<thead>
<tr>
<th>Component</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>5X first strand buffer</td>
<td>8 μl</td>
</tr>
<tr>
<td>DDT</td>
<td>4 μl</td>
</tr>
<tr>
<td>dNTP (10mM each)</td>
<td>2 μl</td>
</tr>
<tr>
<td>SUPERase inhibitor</td>
<td>1 μl</td>
</tr>
<tr>
<td>SuperScript II</td>
<td>1 μl</td>
</tr>
<tr>
<td>Water</td>
<td>4 μl</td>
</tr>
</tbody>
</table>

2.17. Real Time Quantitative PCR

After dilution of the cDNA (1:5 with RNAse-free water) the following mixture was prepared for a total of 20μL of PCR reaction: 10μl of iTaq: 1μl of Taqman probe (20X): 5μl of cDNA: 4μl nuclease-free water. The following Taqman probes (Thermo Fisher Scientific, Waltham, MA, USA) were used for the detection of the mRNA expression levels: UGCG (Hs00916612_m1) and GAPDH (Hs02786624_g1). Real Time PCR was performed by using the Applied Biosystem 7500 Real Time PCR systems and cycle threshold (Ct) values were obtained for the indicated genes. Expression of the target gene was normalized to the internal control gene (GAPDH) and amplification efficiency, and expressed as the mean of normalized expression (MNE) \(^{239,240}\).

2.18. siRNA Transfection

siRNA for \(UGCG\) gene and non-targeting (scrambled) sequence were purchased from Thermo Scientific (Ambion In Vivo #4457298 and #4390843, respectively) and were transfected into cells using the Neon\(^{\text{TM}}\) Transfection System (Invitrogen) as described \(^{241}\). Briefly, 2x10\(^6\) cells for each transfection were prepared as described by the manufacturer, and cells were transfected two times (100nM each siRNA) with a 24h interval in between by using the optimum parameters (pulse voltage: 1350V, pulse width:
10ms, pulse number: 3) in 2ml for the first two hours then diluted to 7ml for longer incubation. Preliminary experiments showed loss of the siRNA effectiveness after 24 hours.

### 2.19. Lipid Analysis by HPLC/MS/MS

Lipid analyses were done in Lipidomics Core Facility in Cancer Center in Stony Brook University, USA. Approximately, $2 \times 10^6$ cells were collected by centrifugation and washed once with 1X PBS. Cell pellets were resuspended in 2ml lipid extraction mixture containing ethyl isopropanol (70%):acetate (2:3, v/v) and the appropriate internal standards. After centrifugation and collection of the supernatant, the cell pellets were reextracted with an additional 2ml of lipid extraction mixture, centrifuged and the supernatants combined for a total of approximately 4ml. Lipid extracts were aliquoted for quantitation of ceramide/sphingoid bases/hexosylceramide and sphingomyelin by LC/MS and for normalization with phospholipids. The samples for MS analysis were first separated chromatographically by using Thermo Accela HPLC (Thermo Fisher Scientific, Waltham, MA, USA). Conditions for operation were optimized with a PEEK Scientific C-8 column (3 μm particle, 4.6 x 150 mm). To maximize intensity and integrity of analytes, the column temperature was set to 30°C by maintaining base line separation in the meantime. Mobile phase A (MPA) was prepared as follows: MS grade water containing 0.2% formic acid and 2 mM ammonium formate (pH 5.6), while mobile phase B (MPB) consisted of: MS grade methanol containing 0.2% formic acid and 1mM ammonium formate (pH 5.6). The conditions for chromatography consisted of: constant gradient for 0.5 min at 70% MPB upon sample injection, followed by an increase to 90% MPB by 5 min, then increased to 99% MPB by 17 min, and kept constant until 26 min; at 26 min, MPB was reduced to 70% within the next 0.5 min and then re-equilibrated for 7 min, for a total gradient of 35 min. For sphingomyelin quantitation, the lipids were first subjected to mild base hydrolysis: 1ml of MeOH and 20μl NaOH is added onto dried SM samples, following a vortex the samples were incubated at room temperature (RT) for 3h. After the incubation period, the samples were vortexed again and 1ml of MeOH, 2ml of chloroform and 1.8ml of H₂O is added into the samples. The samples were vortexed well
after adding each solution to make sure all the solutions are mixed homogenously. Then the samples were centrifuged at 3000rpm for 5 min at RT. After aspirating the upper phase, lower phase is transferred into a clean glass tube without any contamination from upper phase. Transferred lower phase is dried by a SpeedVac vacuum concentrator and dried lipids are resuspended in 100μl of mobile phase. Finally, the following settings were used for LC/MS analysis for sphingomyelin quantitation: upon sample injection the gradient was increased from 60% MPB to 99% MPB over the first 16 min, then maintained at 99% MPB until 29 min into the gradient, at which point the gradient was returned to 60% MPB within 4 min and allowed to equilibrate for the remainder of the 35 min method. For the hexosylceramide quantification conditions for chromatography consisted of: constant gradient for 3 min at 80% MPB upon sample injection, followed by an increase to 99% MPB by 16 min, then stayed at 99% MPB by 29 min, decreased back to 80% MPB for 5 min for a total gradient of 35 min. Detection was accomplished utilizing a Thermo Scientific Quantum Access triple quadrupole mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an Electrospray Ion Source operating in positive ion Multiple Reaction Monitoring (MRM) mode. The HESI source was operated at 400°C vaporizer temperature and 300°C capillary temperature in positive ionization mode with a spray voltage of 4000 V. Gases were set at 60, 0, and 15 for sheath, ion sweep, and auxiliary gases, respectively. Mass spectrometry detection of labeled lipids was accomplished using transitions as described by Snider et al. 242.

2.20. Determination of Inorganic Phosphate (Pi) Concentrations

After taking the samples for lipid determination, 1 ml from the samples were aliquoted into glass tubes and dried by using a nitrogen evaporator. 2 ml of chloroform, 2 ml of methanol and 1.8 ml of dH₂O was added and vortexed well. Tubes were centrifuged at 3000 rpm for 5 min to separate two phases. The upper phase which is the aqueous phase was aspirated and lower phase which has the organic phase is transferred into new glass tubes for Pi analysis. These lipids were dried using a heat block at ~70-80°C and NaH₂PO₄ standards were prepared in separate glass tubes as shown in the Table 2.4.
Table 2.4. Standards used in inorganic phosphate determination.

<table>
<thead>
<tr>
<th>Number of nmoles</th>
<th>1.0mM NaH$_2$PO$_4$</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0 µl</td>
</tr>
<tr>
<td>5</td>
<td>5 µl</td>
</tr>
<tr>
<td>10</td>
<td>10 µl</td>
</tr>
<tr>
<td>20</td>
<td>20 µl</td>
</tr>
<tr>
<td>40</td>
<td>40 µl</td>
</tr>
<tr>
<td>60</td>
<td>60 µl</td>
</tr>
<tr>
<td>80</td>
<td>80 µl</td>
</tr>
</tbody>
</table>

After drying the samples and preparing standards, 600 µl of Ashing buffer is added into each tube and vortexed well. Then the samples were put in a heat block at ~160°C for overnight incubation. Next day, the samples were removed from the heat block and 0.9 ml of H$_2$O, 500 µl of 0.9% ammonium molybdate and 200 µl of 9.0% Ascorbic acid were added into samples and vortexed well. The samples were incubated in a water bath for 30min at 45 °C. 200 µl from each tube was aliquoted in a multiwell plate and read at 600 nm by using a plate reader.

2.21. Measuring In situ GCS Activity by NBD-C6-Ceramide Labeling

Cells were seeded at 0.5x10$^6$cells/ml in 2ml media in a 6-well-plate. At the appropriate time points, 1 µM of NBD-C6-Ceramide (Avanti Polar Lipids, inc.) was added into the media and the cells were collected after 45min of incubation. After the collection of the cells by centrifugation, lipids were extracted as described previously by using lipid extraction buffer. Then the samples were dried by a nitrogen evaporator and dried lipids were reconstituted by 150µl mobile phase. Incorporation of NBD-C6-Ceramide in complex sphingolipids was detected by HPLC conditions equipped with a Fluorescence detector (1260 Infinity, Agilent Technologies). NBD method was run on a
C8 reverse phase column. The fluorescence was read with excitation at 470nm and emission at 530 nm. Mobile Phase A was MS grade water with 1 mM ammonium formate and 0.2% formic acid. Mobile Phase B was MS grade methanol with 1mM ammonium formate and 0.2% formic acid. Mobile Phase C was acetonitrile with 1% formic acid. The method ran 40% A 40% B and 20% C for 3 min. Then ran at a gradient to reach 30% A 65% B and 5% C at the 5 min timepoint. Then continued to adjust the gradient to 10%A 85% B and 5%C at the 20min timepoint and further to 1% A 94% B and 5% C at the 24 min time point. From there the gradient was returned to 40% A 40% B and 20% C at the 26 min timepoint and held there until the end of the 30 min cycle. The method was run at a flow rate of 0.5mL/min. The fluorescent peaks for NBD labeled hexosylceramides were confirmed by the retention times of NBD-C6-Hex standards 243.

2.22. Measuring In situ SK Activity by NBD-Sphingosine Labeling

To measure SK activity, cells were plated at 0.5x10⁶ cells/ml in 2 ml media in a 6-well plate. At the indicated time points, 200 nM of NBD-Sphingosine (Avanti Polar Lipids, inc.) was added into the media and the cells were collected after 15min of incubation. NBD-Sphingosine and NBD-Sphingosine-1-phosphate were detected in HPLC with the same method used in NBD-C6-Ceramide method by using standards.

2.23. Statistical Analyses

All the experiments were repeated as triplicates. The error bars on the graphs represent the standard deviation (SD) from 3 different experiments. Statistical analyses were performed by one-way ANOVA, two-way ANOVA with Bonferroni’s post-test or a Student’s t-test by using GraphPad Prism software (GraphPad Software, San Diego, CA, USA). Asterisks on the plotted graphs indicate statistical significance as *P<0.05, **P<0.01 and ***P<0.001 were significant and P>0.05 was not significant.
CHAPTER 3

RESULTS

3.1. SD-1 Ph+ ALL Cells Show Intrinsic Resistance to Imatinib

Our study aims at testing the possibility of modulating the sphingolipid pathway to sensitize Ph+ ALL cells to imatinib and in particular to sensitize imatinib resistant Ph+ ALL cells. Thus, first off, we wanted to identify a Ph+ ALL cell line intrinsically resistant to the drug. SD-1 and SUP-B15 Ph+ ALL cells have been reported to respond differently to imatinib, with SUP-B15 being more sensitive than SD-1 cells \(^{94}\). To confirm this difference, SD-1 and SUP-B15 cells were exposed to increasing concentrations of imatinib (2, 5, 10 and 20 \(\mu M\) for SD-1 and 0.5, 1, 2, 5 and 10 \(\mu M\) for SUP-B15 cells) for 48h and cell viability was measured by trypan blue exclusion assay.

As shown in Figure 3.1, imatinib decreased the number of viable SUP-B15 cells by \(\sim 50\%\) at 1 \(\mu M\) whereas SD-1 cells required 5 \(\mu M\) and 10 \(\mu M\) imatinib to reduce the viable cells by \(\sim 50\%\) and 70\%, respectively. At this time point with 10 \(\mu M\) imatinib about 20\% of trypan blue positive SD-1 cells were present along with caspase activation. On the other hand, neither trypan blue positive SD-1 cells nor caspase-3 activity could be detected at 5 \(\mu M\) imatinib at 24 h (data not shown) but approximately 20\% of trypan blue cells were detected with 5 \(\mu M\) imatinib at 48 h (data not shown). This data suggests that at lower concentrations imatinib shows cytostatic effects on SD-1 cells whereas as the concentration increases the effect is seen as a mixture with cytotoxicity.

The range of response of SD-1 cells to imatinib (from 0 to 20\(\mu M\)) was confirmed by assessing cell proliferation using MTT assay after 48 h of treatment (Figure 3.2). Similar to the cell number data, taken by trypan blue exclusion assay, the IC\(_{50}\) value for SD-1 cells was calculated to be at 5.5 \(\pm 1.42\) \(\mu M\) (Figure 3.2) for 48 h according to MTT assay results. The further experiments were done by using 5 \(\mu M\) of imatinib as an IC\(_{50}\) value for 48 h. Additionally, 10 \(\mu M\) of imatinib is used to assess the changes of IC\(_{50}\) value for 24 h.
Figure 3.1. Determining the effect of imatinib on the viability of Ph+ ALL cell lines. Cell viability is assessed by trypan blue exclusion assay for SUP-B15 and SD-1 cells seeded at 0.3x10^6 cells/ml in a 6-well plate and exposing to increased concentrations of imatinib from (0-20 μM) for 48 h. The error bars represent the standard deviation (SD) from 3 different experiments.

Figure 3.2. Determining the effect of imatinib on the proliferation of SD-1 cell line. The effect of imatinib on cell proliferation is evaluated by an MTT assay procedure on SD-1 cells incubated with increased concentrations of imatinib (2.5-, 5-, 10-, 15-, 20μM) for 48 h. Results are represented in the graph as the percentage of the absorbance and normalized by untreated control cells. The error bars represent the SD from 3 different experiments.

Overall these results suggest that SD-1 cells tend to be intrinsically more resistant to imatinib compared to SUP-B15 cells, as correlated with the literature and that imatinib showed a more cytostatic effect at lower concentrations (up to 5 μM) and a mixed effect (cytostatic and cytotoxic) at higher concentrations. So, SD-1 cells were found to be
suitable for our studies to mimic the intrinsic resistance seen in Ph+ ALL patients in the clinics.

3.2. SK-1 Inhibition Does Not Contribute to Cytotoxic Effects of Imatinib

Similar to the literature on CML, we wanted to inhibit sphingosine kinase-1 (SK-1) protein activity to be able to get a response in the cell viability with this inhibition. For this purpose, we used the most selective and potent inhibitor of SK-1, known in the literature, PF-543 to get the most specific and maximal inhibition on SK-1 activity. As reported in the literature, the effective concentration for the inhibition of SK-1 by PF543 was at nano molars. Therefore, we tried a range of concentrations starting from 200- up to 800 nM for SD-1 cells and measured SK activity by using HPLC.

As shown in the raw HPLC data in Figure 3.3 NBD labeled sphingosine was detected by the peak at 8.5 min whereas the product NBD-S1P was detected by the peak at 9.5 min based on the data from the standards (data not shown). In the control data set, NBD-Sphingosine and NBD-S1P peak were both giving high fluorescence measured by laser unit (LU) which showed that NBD-labeled S1P was detectable in these cells. Then, with 200 nM of PF543 the NBD-S1P peak is dropped dramatically while with 400 nM of PF543 the drop was even higher and stayed constant by 800 nM PF543 suggesting the maximal inhibition by PF543 is seen by 400 nM.

This data was quantified to see statistical meaning of the changes and as shown in Figure 3.4 it was plotted as S1P/Sph ratio of area under curve (AUC) which corresponds to SK activity. The level of SK activity was almost at 0.8 AUC in the control group, whereas it was decreased to 0.2 AUC by 200 nM of PF543, showing around 75% inhibition.

Moreover, by the application of 400 nM of PF543, SK activity level was detected as around 0.1 AUC which was significantly lower than the one seen by 200 nM of PF543 in which showed around 0.19 AUC. After confirming the inhibitory effect of PF543, 400 nM of PF543 was used in the following experiments as a concentration that showed maximum inhibition of SK activity (Figure 3.4).
Since the effect of imatinib on SK activity was previously described in CML cells, we wanted to see if Ph+ ALL cells have the same regulatory mechanism for SK in presence of imatinib. So, we treated SD-1 cells with imatinib, PF543 and SKI-II at their IC50 and IC50/2 concentrations for 24 hours and detected the SK-1 and SK-2 protein levels by using untreated SD-1 cells as a control group in western blotting. The data showed imatinib treatment decreased SK-1 protein levels similar to the action of SKI-II which is a SK-1 and -2 inhibitor known by its degradant effect on SK proteins suggesting that imatinib is causing either degradation of SK-1 protein or decreasing the expression levels of SK-1 (Figure 3.5). In addition, as seen in the data, PF543 does not change the protein level of SK (Figure 3.5) although the used concentrations of PF543, 200- and 400 nM was shown to inhibit SK activity by 75- and 90%, respectively (Figure 3.4).

On the other hand, SK-2 levels did not change by any of the inhibitors except SKI-II at 10μM (Figure 3.5) which again is known to degrade both SK-1 and SK-2, so the inhibitory effect of imatinib seems to be only through SK-1 but not SK-2 in Ph+ ALL cells. This data also suggests that imatinib does not have any inhibitory effects on SK-2 protein at least at the expression level.

Then, to determine the effect of imatinib on SK activity, we treated the cells with imatinib at IC50 concentration (5 μM), PF543 at its known inhibitory concentration (400nM) and with their combinations and measured SK activity by using NBD-Sphingosine labeling via HPLC. Figure 3.6 shows the SK activity levels in response to different treatments. As seen in figure 3.6, imatinib brings down SK activity levels from 1.8 AUC to around 1.0 AUC at its IC50 concentration. SD-1 cells, treated with PF543, as anticipated, had 0.4 AUC SK activity level (Figure 3.6).

Last but not least, imatinib treatment in combination with PF543 had SK activity levels around 0.25 AUC, showing a partial additive effect with imatinib and PF543 on SK activity (Figure 3.6). Here, we showed that imatinib as well as reducing the protein levels of SK, as previously shown in the western data, also inhibits SK enzyme activity. Additionally, the inhibitory effect on SK activity by imatinib was detected to increase additively in presence of PF543.

Finally, to assess the effects of these changes on cell viability and to see if there is any additive cytotoxic effects of imatinib and PF543; trypan blue exclusion assay was performed to see if the inhibition of SK activity reflects on cell viability in SD-1 Ph+ ALL cells.
Figure 3.3. Analysis of SK activity in response to increased concentrations of PF543 by HPLC. SK activity was measured by production of NBD-Sphingosine-1-phosphate (NBD-S1P) in SD-1 cells treated with NBD-Sphingosine by HPLC on the cells seeded at 0.3x10^6/ml in 6-well plates with (0-, 200-, 400- and 800nM) and without PF543 for 24 h.
Figure 3.4. Quantification of SK activity in response to increased concentrations of PF543. SK activity was measured by production of NBD-S1P in SD-1 cells treated with NBD-Sphingosine by HPLC on the cells seeded at 0.3x10^6/ml in 6-well plates with (200-, 400- and 800nM) and without PF543 for 48 h. The data is plotted as the ratio of S1P/Sph AUC (Area Under Curve) on the y axis. The error bars represent the SD from 3 different experiments. Asterisks indicate statistical significance: ns P>0.05, *P<0.05, **P<0.01, ***P<0.001.

Figure 3.5. The protein levels of SK-1 and SK-2 treated with imatinib, PF543 and SKI-II by western blotting. Protein levels of SK-1 (50kDa) and SK-2 (75kDa) was determined by western blotting, on SD-1 cells seeded at 0.3x10^6/ml treated with imatinib, PF543 and SKI-II for 24 h. β-Actin (42 kDa) was used as internal control.

To this end, SD-1 cells treated with IC_{50} concentration of imatinib (5 μM), 400 nM of PF543, together with their combination were grown for 48 hours and viable cells were counted by using trypan blue dye as described in methods.
Figure 3.6. SK activity in response to imatinib treatment, PF543 and their combination. SK activity was measured by production of NBD-S1P in SD-1 cells treated with NBD-Sphingosine by HPLC on the cells seeded at 0.3x10⁶/ml in 6-well plates with 5 μM of imatinib, 400 nM of PF543, and their combination for 24 h. The data is plotted as the ratio of S1P/Sph AUC on the y axis. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Figure 3.7. Determining the effect of imatinib, PF543 and their combination on cell viability on SD-1 cell line. Cell viability was assessed by trypan blue exclusion assay for SD-1 cells seeded at 0.3x10⁶ cells/ml in a 6-well plate and exposed to PF543 (400 nM), imatinib (5 μM) and their combination for 48 h. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.
Interestingly enough, contrary to the literature, SK-1 inhibition by PF543 did not show any effect on cell viability in SD-1 cells whereas imatinib was showing 50% inhibition on cell viability as anticipated. Moreover, there was no change on cell viability when PF543 was applied together with imatinib (Figure 3.7).

This data is the first in the literature, showing that the additive inhibition of SK-1 enzyme by imatinib and PF543 treatment does not reflect on cell viability in Ph+ ALL cells, which distinguishes this data from the literature. Until now, the only established link between SPLs and Ph+ ALL resided in the role of SK1 and SK2 in the development of this leukemia and as pharmacological targets to sensitize Ph+ ALL cells to imatinib. Interestingly, in SD-1 cells there was no link between SKs and the mechanism of imatinib-induced cytotoxicity or imatinib-resistance in SD-1R cells. These results indicate that the impact of SPL metabolism in the development of imatinib resistance can vary among different cell lines.

3.3. Endogenous Sphingolipid Levels are Elevated in Response to Imatinib in SD-1 Cells

After seeing that there were no additive effects with imatinib and PF543, we wanted to see whether imatinib induces changes in sphingolipids in SD-1 cells. Cells were treated with 10 μM imatinib for 24 h (conditions that elicit a 50% decrease in cell number) and endogenous ceramide and sphingosine levels as well as complex sphingolipids were measured by HPLC/MS/MS as described in the methods. The levels of almost all ceramide species were increased (Figure 3.8, 3.9 and 3.10). While C16-, C18-, C24:1-, C22:1-, and C26:1-ceramides showed a 2-fold increase, C14- and C18:1-ceramides showed 3-fold increase. Some long chain ceramide species (C20-, C20:1-, C24-, and C26-ceramide), although showing a tendency to increase upon treatment with imatinib, were not statistically different from controls (Figure 3.8, 3.9 and 3.10).

Figure 3.8 shows the most abundant ceramides by mass, among all ceramides with different chain length. Additionally, other ceramide species that are relatively less abundant by mass were plotted in Figure 3.9, whereas the least abundant species, in which two of them were not statistically different than controls are shown in Figure 3.10.
Figure 3.8. Analysis of endogenous ceramide levels of SD-1 cells in response to imatinib (most abundant species). SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO) or imatinib (10μM) for 24 h and ceramide (C16-, C18-, C22-, C24:1, C24-ceramide) levels were measured by HPLC/MS as described. The levels of measured sphingolipids were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01, ***P<0.001.

Figure 3.9. Analysis of endogenous ceramide levels of SD-1 cells in response to imatinib (less abundant species). SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO) or imatinib (10μM) for 24 h and ceramide (C14-, C18:1-, C20-, C26:1-ceramide) levels were measured by HPLC/MS as described. The levels of measured sphingolipids were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.
Figure 3.10. Analysis of endogenous ceramide levels of SD-1 cells in response to imatinib (the least abundant species). SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO) or imatinib (10μM) for 24 h and ceramide (C12-, C20:1-, C22:1-, and C26-ceramide) levels were measured by HPLC/MS as described. The levels of measured sphingolipids were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05.

Figure 3.11. Analysis of endogenous sphingolipid levels of SD-1 cells in response to imatinib. SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO) or imatinib (10μM) for 24 h and sphingolipid (dihydrosphingosine, dihydroC16-ceramide and sphingosine) levels were measured by HPLC/MS as described. The levels of measured sphingolipids were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01, ***P<0.01.
In addition to ceramide, other sphingolipids of de novo pathway; dihydrosphingosine (dhSph) and dihydroceramide (dhCer) were also significantly increased upon imatinib treatment. Additionally, we detected 4-fold increase in sphingosine levels in response to imatinib treatment (Figure 3.11).

3.4. Endogenous Complex Sphingolipid Levels are Elevated in Response to Imatinib in SD-1 Cells

To further examine the involvement of sphingolipid metabolism in imatinib treated SD-1 cells, the levels of hexosylceramide (HexCer), a further metabolized product of ceramide, were also detected by HPLC/MS. In addition to ceramide and other sphingolipids of de novo pathway, the levels of complex sphingolipids such as hexosylceramide (HexCer) and sphingomyelin (SM) were also changed by imatinib treatment. Here, the most abundant HexCer species were plotted in Figure 3.12 followed by representing other HexCer species in Figure 3.13.

Analysis of HexCer levels showed a significant 1.5 to 3-fold elevation in C16-, C18:1, C20:1-, C22:1-, and C22-HexCer levels. A 2-fold increase was detected in the levels of C18-, C20-, and C26:1-HexCer in response to imatinib treatment compared to untreated control cells (Figure 3.12 and 3.13). These results suggest that, followed by ceramide generation/accumulation, imatinib is also inducing the conversion of ceramide to HexCer in SD-1 cells. In other words, ceramides are being further metabolized to HexCer by imatinib treatment in Ph+ ALL cells.

In addition to changes in HexCer levels, we also examined the changes in another major sphingolipid, sphingomyelin (SM) levels in response to imatinib. As shown in (Figure 3.14 and 3.15); C14- and C16-SM exhibited the greatest changes by having more than 2-fold increase, whereas C18-, C18:1-, C20-, C22:1-, and C24:1-SM levels were elevated almost 2-fold after treatment with 10 μM imatinib for 24 h (Figure 3.14, 3.15 and 3.16).

All these results show for the first time in the literature that imatinib induces an increase in the levels of sphingolipids starting from de novo pathway sphingolipids, continued by an increase in ceramide and sphingosine levels which both are cytotoxic.
sphingolipids in these SD-1 Ph+ ALL cells. The increase in ceramide results in further metabolization of imatinib to HexCer and SM.

Figure 3.12. Analysis of endogenous hexosylceramide levels of SD-1 cells in response to imatinib (most abundant species). SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO) or imatinib (10μM) for 24 h and HexCer (C16-, C18-, C20-, C22-, C24:1-, C24-, and C26:1-hexosylceramide) levels were measured by HPLC/MS as described. The levels of measured sphingolipids were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01, ***P<0.001.

Overall, these data suggest that sphingolipid metabolism is involved in response to imatinib in SD-1 cells by:

(i) increasing ceramide and sphingosine levels, either by inducing their generation in a greater rate or by preventing the further metabolization of these sphingolipids and causing their accumulation;

(ii) inducing further metabolization of ceramide into two group of complex sphingolipids, SM and HexCer either by increasing the flux through ceramide or by blocking the further catabolism of these complex sphingolipids.

Importantly, the increase in the levels of dhSph and dhCer, both of which are upstream of ceramide in de novo synthesis pathway, suggests that ceramide and sphingosine accumulation in response to imatinib treatment is very likely to be due to an induction of de novo synthesis pathway of sphingolipids.
Figure 3.13. Analysis of endogenous hexosylceramide levels of SD-1 cells in response to imatinib (less abundant species). SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO) or imatinib (10μM) for 24 h and HexCer (C14-, C18:1-, C20:1-, C22:1-, and C26-hexosylceramide) levels were measured by HPLC/MS as described. The levels of measured sphingolipids were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01, ***P<0.001.

Figure 3.14. Analysis of endogenous sphingomyelin levels of SD-1 cells in response to imatinib (most abundant species). SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO) or imatinib (10μM) for 24 h and SM (C16-, and C24:1-sphingomyelin) levels were measured by HPLC/MS as described. The levels of measured sphingolipids were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01, ***P<0.001.
Figure 3.15. Analysis of endogenous sphingomyelin levels of SD-1 cells in response to imatinib (less abundant species). SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO) or imatinib (10μM) for 24 h and SM (C14-, C18-, C20-, C22:1-, C22-, and C24-sphingomyelin) levels were measured by HPLC/MS as described. The levels of measured sphingolipids were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.

Figure 3.16. Analysis of endogenous sphingomyelin levels of SD-1 cells in response to imatinib (the least abundant species). SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO) or imatinib (10μM) for 24 h and SM (C18:1-, C20:1-, C26-, and C26:1-sphingomyelin) levels were measured by HPLC/MS as described. The levels of measured sphingolipids were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01, ***P<0.001.
On the other hand, S1P levels were barely detectable in every experimental condition (data not shown). Overall these results suggest that treatment with imatinib in SD-1 cells affects the levels of multiple endogenous sphingoid bases and ceramides possibly through induction of \textit{de novo} sphingolipid synthesis.

\textbf{3.5. De novo Sphingolipid Synthesis Pathway is Induced by Imatinib in SD-1 Cells}

Since the observed changes in sphingolipid levels seemed to affect every step of the \textit{de novo} biosynthetic pathway, we investigated whether these lipid changes were due to activation of this specific pathway. Thus SD-1 cells were pre-treated with 500 nM myriocin, an SPT inhibitor that blocks the very first step in \textit{de novo} sphingolipid synthesis, for 1 h and exposed to 10 $\mu$M imatinib for 24 h and sphingolipid levels were measured and compared to control cells. Effectiveness of myriocin treatment was confirmed by the reduction of dhSph and dhCer levels in control cells (Figure 3.17).

![Figure 3.17](image)

Figure 3.17. Analysis of \textit{de novo} sphingolipids in response to myriocin; A. dihydroyC16-ceramide levels, B. dihydroyceramide levels. SD-1 cells, grown in T25 flasks (0.3x10$^6$ cells/ml) were treated with vehicle (DMSO), imatinib (10$\mu$M) and myriocin (500nM) for 24 h and dhCer and dhSph levels were measured by HPLC/MS as described. The sphingolipid levels were normalized to Pi concentrations, and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns $P>0.05$, *$P<0.05$. 

65
While treatment with imatinib (10 μM for 24 h) increased total ceramide levels as expected, treatment with myriocin significantly reduced the accumulation of ceramide which reached levels similar to untreated cells (Figure 3.18). Similar results were observed in the case of sphingosine (Figure 3.19). The increase in sphingosine levels with imatinib treatment is almost completely prevented by presence of myriocin suggesting that similar to the ceramide levels, sphingosine levels that are increased by imatinib is also due to induction of de novo synthesis pathway but not through recycling pathway (Figure 3.19).

These data suggest that imatinib treatment in SD-1 cells activates de novo sphingolipid synthesis and that this pathway contributes significantly to imatinib-induced accumulation of cytotoxic sphingolipids such as ceramide and sphingosine.

Next, to determine the origin of increased HexCer levels in response to imatinib, HexCer levels were measured in the same experimental setting with myriocin treatment.

![Figure 3.18](image)

Figure 3.18. The changes in total ceramide levels with imatinib treatment in presence of myriocin. SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (10μM), myriocin (500nM) and myriocin (500nM)+imatinib(10μM) for 24 h and ceramide levels were measured by HPLC/MS as described. The sphingolipid levels were normalized to Pi concentrations, all the ceramide species were summed, and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD standard deviation (SD) from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Figure 3.19. The changes in sphingosine levels with imatinib in presence of myriocin. SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (10μM), myriocin (500nM) and myriocin+imatinib for 24 h and sphingosine levels were measured by HPLC/MS as described. SPL levels were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05.

Interestingly, HexCer levels were diminished from 4.2 pmol/nmol Pi in untreated control cells to 1.2- and 1.5 pmol/nmol Pi in myriocin and myriocin and imatinib cotreated cells, respectively (Figure 3.20). As anticipated, imatinib alone treatment increased HexCer levels by almost 2-fold compared to control cells (Figure 3.20). These data suggested that inhibition of de novo ceramide synthesis is sufficient to prevent the accumulation of HexCer in response to imatinib and therefore HexCer generated by imatinib induction completely relies on de novo synthesized ceramide.

Additionally, we measured SM levels in the same experimental setting detailed above, to see whether the increase in this sphingolipid by imatinib treatment is also hailed from de novo synthesis pathway. The data showed that even though both myriocin alone and myriocin and imatinib cotreatment decreased SM levels by 21.1- and 17.6% respectively, compared to control cells, the change was detected as not significant (Figure 3.21).

These results suggest that, blocking de novo synthesis of ceramide is not fully reflected on SM production induced by imatinib which might be due to either need of more time to observe an effect on SM levels or HexCer being the predominant complex sphingolipid utilizing de novo synthesized ceramide.
Figure 3.20. The changes in total hexosylceramide levels with imatinib in presence of myriocin. SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (10μM), myriocin (500nM) and myriocin+imatinib for 24 h and HexCer levels were measured by HPLC/MS as described. HexCer levels were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns, **P<0.01, ***P<0.001.

Figure 3.21. The changes in total sphingomyelin levels with imatinib in presence of myriocin. SD-1 cells, grown in T25 flasks (0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (10μM), myriocin (500nM) and myriocin+imatinib for 24 h and SM levels were measured by HPLC/MS as described. The SM levels were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01, ***P<0.001.
All together the lipid results support a scenario whereby imatinib induces *de novo* sphingolipid synthesis in SD-1 Ph+ ALL cells. Then, dihydrosphingosine and dihydroceramide are produced and these reactions are followed by sphingosine and ceramide production through *de novo* induction, in which then fluxed further and converted in part into hexosylceramide and sphingomyelin by the action of GCS and SMS enzymes. Since the conversion to HexCer is seen clearly at the indicated time point, the data suggests that the activity of GCS enzyme is at a high rate.

### 3.6. Activation of *de novo* Sphingolipid Synthesis Participates in the Cytostatic Response to Imatinib Treatment of SD-1 Cells

To assess whether the sphingolipids that are generated through the *de novo* pathway are involved in the cytotoxic effect of imatinib in SD-1 cells, the effect of inhibition of the *de novo* pathway on cell viability was tested upon imatinib treatment. SD-1 cells were pre-treated with 500 nM myriocin for 1 h followed by addition of 10 μM imatinib for 24 h and viable cells were counted by trypan blue exclusion assay. As shown in Figure 3.22, there were no significant changes between the number of control cells (0.69x10^6 cells/ml) and myriocin treated cells (0.64x10^6 cells/ml) suggesting that myriocin, at the concentration employed, was not toxic to the cells.

As expected, imatinib treatment inhibited cell growth by ~50% resulting in 0.34x10^6 cells/ml; importantly, pretreatment with myriocin brought back the number of imatinib treated cells at 0.55 x10^6 cells/ml (Figure 3.22), thus significantly reverting the cytotoxic / cytostatic effect of the drug. These results suggest that sphingolipids produced via *de novo* synthesis contribute to the inhibitory effect of imatinib on cell number in SD-1 cells.

Since treatment with imatinib caused accumulation of the cytotoxic/cytostatic sphingolipids; ceramide and sphingosine and the levels of both these lipids were significantly reduced by myriocin (Figure 3.18 and 3.19), while myriocin also protected from the cytotoxic / cytostatic effects of imatinib (Figure 3.22), we wondered whether one of these two lipids were responsible for the observed cytotoxic / cytostatic effects of imatinib.
Figure 3.22. Contribution of *de novo* sphingolipid pathway to cytotoxic effects of imatinib in SD-1 cells. Cell viability is assessed by trypan blue exclusion assay for SD-1 cells seeded at 0.3x10⁶ cells/ml and treated with vehicle (DMSO), myriocin (500nM), imatinib (10μM) and myriocin+imatinib for 24 h. The error bars represent the SD from 3 different experiments. ns P>0.05, **P<0.01.

Figure 3.23. The effect of exogenous treatment with C6-ceramide on cell viability. The effect of exogenous treatment with C6-ceramide (0-, 5-, 10-, and 20 μM) on cell viability is evaluated by trypan blue exclusion assay on SD-1 cells seeded at 0.3x10⁶ cells/ml for 48 hours. The error bars represent the SD from 3 different experiments.
Thus, the effect on cell number of exogenous treatments with either one of these lipids was determined. As shown in Figure 3.23, SD-1 cells were treated with increasing concentrations of the cell permeable ceramide analogue C6-ceramide (from 0 to 20 μM) for 48h and the cell number was determined by trypan blue exclusion assay as previously described. A dose dependent inhibitory effect of C6-ceramide was observed already at 5 μM (30% decrease compared to control cells) which increased with increasing concentrations of the lipid, reaching a 70% growth inhibition at 20 μM (Figure 3.23).

Interestingly, exogenous addition of sphingosine was also effective similar to C6-ceramide. Sphingosine treatment showed growth inhibitory effects starting slightly by 2.5 μM and gradually continued as the concentration increases. The inhibitory effect of sphingosine was similar to what was seen with C6-ceramide treatment by showing 50% decrease in cell viability at 7.5 μM together with further cytotoxicity with 10 μM sphingosine (Figure 3.24). Finally, the growth of more than 80% of the cells were habituated by 10 μM sphingosine treatment.

Figure 3.24. The effect of exogenous treatment with sphingosine on cell viability. The effect of exogenous treatment with sphingosine (0-, 2.5-, 5-, 7.5- and 10 μM) on cell viability is evaluated by trypan blue exclusion assay on SD-1 cells seeded at 0.3x10⁶ cells/ml for 24 h.

All together these results point to imatinib-induced stimulation of the \textit{de novo} sphingolipid pathway which contributes to accumulation of cytotoxic/cytostatic sphingolipids (ceramide and sphingosine), and they show that a significant portion of the ceramide formed from the \textit{de novo} pathway in response to imatinib is being also converted into more complex sphingolipids (HexCer and SM).
3.7. Pharmacological Inhibition of GCS Exacerbates the Accumulation of Cytostatic/Cytotoxic Sphingolipids Induced by Imatinib and Sensitizes SD-1 Cells to the Drug

Given that a portion of ceramide generated in response to imatinib treatment in SD-1 cells is shunted through HexCer and that accumulation of ceramide or of the metabolically connected sphingosine could be one of the mechanisms of imatinib induced cytotoxicity, we sought to test the effects of enhancing accumulation of ceramide (and possibly sphingosine) by blocking its conversion into HexCer. HexCer measurements represent the combination of glucosylceramide (GluCer) and galactosylceramide (GalCer) levels, thus first, we determined the contribution of GluCer to HexCers levels. To this aim, we employed eliglustat, a potent FDA approved specific inhibitor of GCS and currently utilized for the treatment of Gaucher’s disease, a lysosomal storage disorder characterized by the toxic accumulation of GluCer\textsuperscript{245,246}.

![Graphs](image)

**Figure 3.25.** The effects of eliglustat treatment on GCS activity measured by production of A. NBD-C6-hexosylceramide and B. hexosylceramides. A. SD-1 cells treated with NBD-C6-ceramide by HPLC on the cells seeded at 0.3x10\(^6\)/ml in 6-well plates with and without eliglustat (100 nM) for 24 and 48 hours. The data is plotted as AUC on the y axis. B. The effect of eliglustat (100nM) treatment for 24 hours on the total levels of hexosylceramide measured by HPLC/MS. The error bars represent the SD from 3 different experiments. ns \(P>0.05\), \(*P<0.05\), \(**P<0.01\), \(***P<0.001\).
Cells were treated with 100 nM eliglustat for 24 and 48h and, for each time point, 1 μM NBD-C6-ceramide was added 1h before collecting the cells. Lipids were extracted and NBD-C6-ceramide and NBD-C6-GluCer were measured by HPLC/MS/MS. As shown in Figure 3.25, 100 nM eliglustat exerted ~ 90% inhibition of GCS activity at both 24h and 48h. Importantly, inhibition of GCS activity by 24h treatment with 100 nM eliglustat was also confirmed by measuring endogenous HexCer levels by HPLC/MS. Total HexCer levels decreased from 4.0 pmol/nmol Pi to 0.6 pmol/nmol Pi in eliglustat treated SD-1 cells (Figure 3.26). Importantly, these results show the efficacy of inhibition of GCS by eliglustat and they reveal that GluCer is far more abundant than GalCer as HexCers are mostly gone after inhibition of GCS.

![Figure 3.26](image)

Figure 3.26. The changes in the total ceramide levels of SD-1 cells treated with imatinib and eliglustat and their combination. SD-1 cells, grown in T25 flasks (seeded at 0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (5μM), eliglustat (100nM) and eliglustat (100nM)+imatinib(5μM) for 24 h and ceramide levels were measured by HPLC/MS as described. The ceramide levels were normalized to Pi concentrations, all the ceramide species were summed and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.

Next, to see the effect of pharmacological inhibition of GCS on imatinib induced changes in endogenous sphingolipid levels, sphingolipid levels were detected as described before. The data showed that total ceramide levels are increased from 1.69
pmol/nmol Pi in control cells to 2.07 pmol/nmol Pi in 5 μM imatinib treated cells (Figure 3.26). Although total ceramide levels are not significantly changed with eliglustat treatment, they further increased with eliglustat and imatinib cotreatment to an absolute level of 3.47 pmol/nmol Pi.

Figure 3.27. The changes in the total hexosylceramide levels of SD-1 cells treated with imatinib and eliglustat and their combination. SD-1 cells, grown in T25 flasks (seeded at 0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (5μM), eliglustat (100nM) and eliglustat (100nM)+imatinib(5μM) for 24 h and HexCer levels were measured by HPLC/MS as described. The HexCer levels were normalized to Pi concentrations, all the HexCer species were summed and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.

Additionally, total hexosylceramide levels were decreased by 85% with eliglustat treatment and stayed at the similar levels with imatinib in presence of eliglustat, suggesting that ceramide production through *de novo* synthesis in response to imatinib can no longer be shunted through hexosylceramide in presence of eliglustat (Figure 3.27). On the other hand, sphingomyelin levels are not significantly changed by imatinib and eliglustat treatment separately whereas it increases by ~90% with eliglustat and imatinib cotreatment (Figure 3.28). This data suggests that, ceramide produced by imatinib is further shunted towards sphingomyelin in case of a blockage in flux through hexosylceramides.
Figure 3.28. The changes in the total sphingomyelin levels of SD-1 cells treated with imatinib and eliglustat and their combination. SD-1 cells, grown in T25 flasks (seeded at 0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (5μM), eliglustat (100nM) and eliglustat (100nM)+imatinib(5μM) for 24 h and SM levels were measured by HPLC/MS as described. The SM levels were normalized to Pi concentrations, all the SM species were summed and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05.

Additionally, another member of sphingolipids; sphingosine too, similar to the changes in ceramide, is increased by more than 2-fold in imatinib treated cells and further increased by ~5 fold with imatinib and eliglustat cotreatment (Figure 3.29). While control cells have sphingosine levels at around 0.1 pmol/nmol Pi, imatinib treatment elevated sphingosine levels to the levels of 2.5 pmol/nmol Pi. In presence of eliglustat, imatinib is able to further increase sphingosine levels to over 0.4 pmol/nmol Pi. This data is suggesting that in addition to ceramide, sphingosine is also accumulated by imatinib treatment in presence of eliglustat.

Overall these results show that we were able to further increase ceramide and sphingosine levels with imatinib treatment at sub-growth inhibitory concentrations by blocking the flux through hexosylceramide with eliglustat. Overall these results show that blocking the flux through glucosylceramide with eliglustat effectively enhances the effects of imatinib on accumulation of the cytotoxic sphingolipids, ceramide and sphingosine.
Figure 3.29. The changes in the sphingosine levels of SD-1 cells treated with imatinib and eliglustat and their combination. SD-1 cells, grown in T25 flasks (seeded at 0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (5μM), eliglustat (100nM) and eliglustat (100nM)+imatinib(5μM) for 24 h and sphingosine levels were measured by HPLC/MS as described. The sphingosine levels were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.

We further investigated the effect of modulation of these sphingolipids on the antiproliferative effect of imatinib on SD-1 cells. Therefore, using the same experimental settings as above, SD-1 cells were pretreated with 100nM of eliglustat and then exposed to 5μM imatinib for 24 and 48h and cell number was assessed by trypan blue exclusion assay. Whereas treatment with imatinib alone inhibited SD-1 proliferation by ~30% at 24h, cotreatment of imatinib and eliglustat significantly enhanced this effect (~50%).

Interestingly, eliglustat by itself did not exhibit any effect on cell proliferation, suggesting a synergistic cytostatic effect on these cells with eliglustat and imatinib treatment (Figure 3.30). The synergistic effect of eliglustat and imatinib could also be seen at 48h where imatinib treatment inhibited SD-1 cell number by ~50% at 48h and the combination further inhibited it by ~75% (Figure 3.30). These data demonstrate that, enhancing accumulation of cytotoxic sphingolipids like ceramide and sphingosine by inhibiting GCS activity, result in sensitization of SD-1 cells to the anticarcinogenic effects of imatinib.
3.8. The Effect of siRNA Mediated Knock-Down of GCS on Imatinib Induced Changes in Endogenous Sphingolipid Levels and Cell Number of SD-1 Cells

To confirm that the observed effects with eliglustat treatment were actually due to GCS inhibition and not to off-target effects, we tested the effects of downregulation of GCS on lipids and cell number alone and in combination with imatinib. GCS expression was silenced with different amounts of siRNA while non-targeting siRNA was used as control.

Several concentrations of siRNA and modalities of transfection were tested and analysis of mRNA expression by Real Time PCR revealed that the maximal down-regulation of GCS was obtained with 100 nM siRNA (Figure 3.31 A); on the other hand, this resulted in a little over 50% decrease of in situ glucosylceramide synthase (GCS) activity as measured by the conversion of NBD-C6-ceramide into NBD-C6-hexosylceramide (Figure 3.31 B).
Figure 3.31. The effects of GCS siRNA transfection on GCS activity measured by A. GCS mRNA levels and B. NBD-C6-hexosylceramide levels. SD-1 cells, grown in T25 flask (total 2x10^6 cells) transfected with 100nM of siRNA for 24 h and the effects of GCS siRNA and control siRNA (non-targeting scrambled) was measured as A. GCS mRNA expression level is measured by Real-Time PCR as described in the methods. Expression of mRNA is normalized to GAPDH and represented as mean normalized expression (MNE). B. GCS activity is detected by measuring NBD-C6-hexosylceramide levels by HPLC as described in the methods. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05.

Then, 24 h after the transfection with control and GCS siRNAs, the cells were exposed to 5μM imatinib for additional 24 h and endogenous sphingolipid levels were measured by HPLC/MS. As shown in Figure 3.32, although imatinib treatment in control siRNA transfected cells increased the hexosylceramide levels in SD-1 cells; total hexosylceramide production was inhibited by ~50% with GCS siRNA treatment and stayed at the same level when imatinib is applied (Figure 3.32).

On the other hand, ceramide levels were elevated significantly with only GCS siRNA treatment compared to control cells. As anticipated, imatinib treatment increased the ceramide levels by ~40% in control siRNA transfected cells and by ~80% in the cells which GCS is silenced by siRNA.

Overall these data suggest that, reflecting the sphingolipid levels changes observed in eliglustat and imatinib cotreatment; imatinib treated cells are able to further accumulate ceramide levels when GCS is silenced, and ceramide is no longer able to be converted to hexosylceramide in the cells (Figure 3.33).
Figure 3.32. Effect of GCS knockdown and imatinib treatment on the levels of hexosylceramides in SD-1 cells. 24 hours after the transfection with control and GCS siRNAs, SD-1 cells were treated with vehicle (DMSO) or imatinib (5 μM) for 24 h and HexCer levels were measured by HPLC/MS as described. HexCer levels were normalized to Pi concentrations, and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.

Figure 3.33. Effect of GCS knockdown and imatinib treatment on the levels of ceramide in SD-1 cells. 24 hours after the transfection with control and GCS siRNAs, SD-1 cells were treated with vehicle (DMSO) or imatinib (5μM) for 24 h and ceramide levels were measured by HPLC/MS as described. Ceramide levels were normalized to Pi concentrations, and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05 **P<0.01.
Furthermore, sphingomyelin levels are increased with imatinib treatment as anticipated from previous data whereas GCS inhibition by siRNA also showed an increase in the sphingomyelin levels suggesting that in case of a blockage on the pathway through hexosylceramides, ceramide is converted to sphingomyelin in a greater rate. Additionally, when imatinib is applied to GCS siRNA transfected cells, sphingomyelin levels are increased even more, showing an additional effect on the increase in sphingomyelin levels (Figure 3.34).

Sphingosine levels are changed in a similar manner to the other sphingolipids. Imatinib treatment increased sphingosine levels by ~4-fold in control cells whereas it increased sphingosine accumulation by ~7-fold in GCS siRNA transfected cells (Figure 3.35). This data suggests that as well as ceramide levels, sphingosine level is also additively increasing with imatinib treatment on GCS siRNA transfected cells.

![Figure 3.34. Effect of GCS knockdown and imatinib treatment on the levels of sphingomyelin in SD-1 cells. 24 hours after the transfection with control and GCS siRNAs, SD-1 cells were treated with vehicle (DMSO) or imatinib (5 μM) for 24 h and SM levels were measured by HPLC/MS as described. The SM levels were normalized to Pi concentrations, all the SM species were summed, and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the standard deviation (SD) from 3 different experiments. Asterisks indicate statistical significance: ns P>0.05, *P<0.05.](image)

Finally, we wanted to see whether these changes in sphingolipids are implicated in the proliferation phenotype, we examined the changes in cell viability with trypan blue exclusion assay on GCS siRNA transfected cells with and without imatinib treatment.
Figure 3.35. Effect of GCS knockdown and imatinib treatment on the levels of sphingosine in SD-1 cells. 24 hours after the transfection with control and GCS siRNAs, cells were treated with vehicle (DMSO) or imatinib (5μM) for 24 h and sphingosine levels were measured by HPLC/MS as described. Sphingosine levels were normalized to Pi concentrations and represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments.: ns P>0.05, *P<0.05, **P<0.01, ***P<0.001.

Figure 3.36. Effect of GCS knockdown together with imatinib treatment on cell viability in SD-1 cells. Cell viability is assessed by trypan blue exclusion assay for SD-1 cells transfected with control and GCS siRNAs and then treated with imatinib (5μM) for 24 hours. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.
Correlatively to the previous data, imatinib treatment on control cells inhibited cell proliferation by 30% and by 50% where GCS is silenced by siRNA in SD-1 cells (Figure 3.36). Together these data confirm that synergistic cytostatic effect of imatinib and eliglustat cotreatment is actually due to GCS inhibition since similar changes both at sphingolipid and cell proliferation level were seen by inhibiting GCS expression with siRNA transfection. Again, these data strengthen the idea of blocking the sphingolipid flux through by inhibiting GCS can be used as a treatment approach to sensitize SD-1 cells to imatinib treatment by increasing the endogenous ceramide and/or sphingosine levels.

3.9. Generation of Imatinib Resistant SD-1 Cells (SD-1R)

Considering the clinical relevance of imatinib resistance in the treatment of Ph+ ALL, we sought to test the efficacy of targeting sphingolipid metabolism in imatinib-resistant Ph+ ALL cells. To this aim, we generated an imatinib resistant SD-1 cell line to mimic development of secondary resistance in Ph+ ALL patients who are receiving TKI treatment. Secondary resistance is likely acquired by cells that are intrinsically more resistant, survive treatment and continue to be exposed to the drug. Since SD-1 cells are intrinsically more resistant to imatinib than other Ph+ ALL cell lines (Figure 3.1), they were selected for this purpose and they were exposed to gradually increasing concentrations of imatinib starting from 0.05 μM. During the process, imatinib concentration is doubled when the cells reach the same confluency and growth rate as parental cell line. The escalation of the dose was stopped when the newly generated resistant cell line was able to be maintained in the presence of 10 μM of imatinib in the medium and they are referred to as SD-1R cells. The detailed protocol for generation of resistant cell line can be found in methods section (Figure 2.1).

In these conditions, parental SD-1 cells showed more than a 70% inhibition of viable cells whereas SD-1R showed no significant change at 48 h (Figure 3.37 A). Cell viability was also measured by MTT assay at 48h of treatment with increasing concentrations of imatinib (Figure 3.37 B). As shown in the figure, IC$_{50}$ value are calculated at ~5 μM and ~15 μM for parental SD-1 and SD-1R cells, respectively, with
a 3-fold increase of resistance in newly generated imatinib resistant SD-1R cells compared to parental cell line.

Resistance of SD-1R to imatinib was also confirmed by absence of caspase-3 cleavage in response to imatinib (Figure 3.38 A). In fact, while imatinib treatment was found to increase caspase-3 cleavage in SD-1 cells, caspase 3 activation was not detected in SD-1R cells. Since we saw a change in an apoptotic protein we wanted to check if any other apoptotic proteins are involved into imatinib resistance in SD-1R cells. To this end, we checked the protein levels of BCL2 and BCL-XL but there was no change at the levels of these proteins between sensitive and resistant cells (Figure 3.38 B).

Figure 3.37. Comparative response to imatinib treatment by SD-1 and SD-1R cells measured by A. trypan blue assay B. MTT assay. A.Cell viability is assessed by trypan blue exclusion assay for SD-1 and SD-1R cells seeded at 0.3x10⁶ cells/ml in a 6-well plate and treated with 10μM imatinib for 48 h. B.The effect of imatinib on cell viability is evaluated by an MTT assay procedure on SD-1 and SD-1R cells incubated with increased concentrations of imatinib (2.5-, 5-, 10-, 15-, 20μM) for 48 h. Results are represented in the graph as the percentage of the absorbance and normalized by untreated control cells. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.
Lastly, we wanted to check one of the commonly seen type of resistance mechanism in BCR/ABL positive cells which is elevating the levels of BCR/ABL as previously indicated by various studies both in CML and Ph+ ALL cases.

As seen in Figure 3.38 C, SD-1R cells revealed increased levels of BCR/ABL protein suggesting that newly generated SD-1R cells showed an increase in BCR/ABL protein levels suggesting this upregulation as a contributor to the resistance mechanism in these cells. Since upregulation of BCR/ABL levels is a common resistance mechanism for BCR/ABL positive cells, this data indicates similar to other BCR/ABL positive cell lines, SD-1R cells might reveal a BCR/ABL dependent mechanism for imatinib resistance.

Figure 3.38. Mechanism of resistance to apoptosis induced by imatinib in SD-1R cells. A. Cleaved caspase-3, BCL2 and BCL-XL C. BCR/ABL levels. A. Cleaved caspase-3 (17-19kDa) levels B. Levels of apoptotic proteins BCL2 (26kDa) and BCL-XL (30kDa) C. BCR/ABL (190 kDa) protein levels were determined by western blotting on SD-1 and SD-1R cells treated with $10\mu$M imatinib for 48 h. GAPDH (37kDa) is used as internal control representing a housekeeping protein.
3.10. Blunted Imatinib Induced Changes in Endogenous Sphingolipid Levels of SD-1R cells

To test whether targeting sphingolipid metabolism could also sensitize imatinib-resistant Ph+ ALL cells in addition to parental SD-1 cells, we first assessed the changes in sphingolipid profile between SD-1 and SD-1R cells by HPLC/MS/MS following imatinib treatment with 10 μM for 24 h (Figure 3.39, 3.40, 3.41, 3.42). While imatinib treatment resulted in a significant increase in total ceramide levels in SD-1 cells no changes were observed in SD-1R cells (Figure 3.39), suggesting that failure to accumulate ceramide might be involved in resistance to imatinib in SD-1R cells.

Figure 3.39. Changes in endogenous ceramide levels of SD-1 and SD-1R cells in response to imatinib. SD-1 and SD-1R cells are seeded at 0.3x10⁶ cells/ml in a 6-well plate and treated with vehicle (DMSO) or 10 μM imatinib for 24 h and ceramide levels were measured by HPLC/MS as described. The ceramide levels were normalized to Pi concentrations and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.

Interestingly, total HexCer levels were similarly elevated in both SD-1 and SD-1R cells (Figure 3.40) indicating that this metabolic pathway is still operational in SD-1R cells. Therefore, the data suggest that imatinib resistance in SD-1R cells is associated to a deficiency in production but not in further metabolization of ceramide. Additionally, while sphingosine levels were increased by ~3-fold following imatinib treatment in SD-1 cells, they seemed to trend towards an increase in SD-1R cells, although the change is
not statistically significant (Figure 3.41). Furthermore, while SM levels increased significantly in SD-1 cells, they remained unchanged in SD-1R cells (Figure 3.42).

Figure 3.40. Changes in endogenous hexosylceramide levels of SD-1 and SD-1R cells in response to imatinib. SD-1 and SD-1R cells are seeded at 0.3x10^6 cells/ml in a 6-well plate and treated with vehicle (DMSO) or 10μM imatinib for 24 h and HexCer levels were measured by HPLC/MS as described. HexCer levels were normalized to Pi concentrations, final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05.

Figure 3.41. Changes in endogenous sphingosine levels of SD-1 and SD-1R cells in response to imatinib. SD-1 and SD-1R cells are seeded at 0.3x10^6 cells/ml in a 6-well plate and treated with vehicle (DMSO) or 10μM imatinib for 24 h and sphingosine levels were measured by HPLC/MS as described. The sphingosine levels were normalized to Pi concentrations and represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, ***P<0.001.
Figure 3.4.2. Changes in endogenous sphingomyelin levels of SD-1 and SD-1R cells in response to imatinib. SD-1 and SD-1R cells are seeded at 0.3x10^6 cells/ml in a 6-well plate and treated with vehicle (DMSO) or 10μM imatinib for 24 hours and sphingomyelin levels were measured by HPLC/MS as described. The SM levels were normalized to Pi concentrations and represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.

Overall, these results showed a blunted sphingolipids response of SD-1R cells to imatinib compared to sensitive SD-1 cells (the overall sphingolipids changes were significantly reduced compared to sensitive SD-1 cells) and growth inhibitory sphingolipids were not accumulated; however, they also demonstrated a preserved ability of these cells to channel sphingolipids towards HexCers in response to imatinib.

### 3.11. Inhibition of GCS in Combination with Imatinib Treatment Promotes Accumulation of Growth Inhibitory Sphingolipids and Re-Sensitizes SD-1R Cells to the Drug

Next, we applied the same treatment strategy as used in SD-1 cells to modulate sphingolipid metabolism in order to accumulate ceramide and/or sphingosine levels to see whether this intracellular changes in sphingolipid levels could overcome imatinib resistance in SD-1R cells. For this purpose, cells were treated with 10 μM imatinib, the concentration that they grow with in media with or without 100 nM eliglustat pre-treatment and sphingolipid levels were detected as described above. Begin with, the data
showed that eliglustat treatment decreased hexosylceramide levels to 1.07 pmol/nmol Pi and kept them at 1.55 pmol/nmol Pi when imatinib added onto eliglustat; although they are increased to 6.04 pmol/nmol with imatinib alone treatment compared to 3.8 pmol/nmol hexosylceramides in control cells (Figure 3.43). This data is suggesting that eliglustat is inhibiting GCS activity and blocking the conversion of ceramide to hexosylceramides in SD-1R cells similar to SD-1 cells.

Additionally, total ceramide levels are elevated by 2-fold with eliglustat and imatinib cotreatment although imatinib and eliglustat alone treatments also showed an increase but not as much in total ceramide levels suggesting a synergistic effect on the accumulation of ceramides with eliglustat and imatinib cotreatment (Figure 3.44).

Furthermore, treatment with imatinib alone increased the levels of sphingosine by 2-fold while it resulted in a further increase by more than 3-fold in presence of eliglustat (Figure 3.45). Again, this data suggests that, similar to the effect on ceramides, imatinib and eliglustat cotreatment shows a synergistic increase in the levels of sphingosine in SD-1R cells.

Figure 3.43. The changes in the hexosylceramide levels of SD-1R cells treated with imatinib and eliglustat and their combination. SD-1 cells, grown in T25 flasks (seeded at 0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (10μM), eliglustat (100nM) and eliglustat+imatinib for 24 h and HexCer levels were measured by HPLC/MS as described. HexCer levels were normalized to Pi concentrations final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05.
Figure 3.44. The changes in the ceramide levels of SD-1R cells treated with imatinib and eliglustat and their combination. SD-1 cells, grown in T25 flasks (seeded at 0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (10μM), eliglustat (100nM) and eliglustat +imatinib for 24 h and ceramide levels were measured by HPLC/MS as described. The ceramide levels were normalized to Pi concentrations, all the sphingolipid species were summed, and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05.

Figure 3.45. The changes in the sphingosine levels of SD-1R cells treated with imatinib and eliglustat and their combination. SD-1 cells, grown in T25 flasks (seeded at 0.3x10^6 cells/ml) were treated with vehicle (DMSO), imatinib (10μM), eliglustat (100nM) and eliglustat +imatinib (10μM) for 24 h and sphingosine levels were measured by HPLC/MS as described. The sphingosine levels were normalized to Pi concentrations, all the sphingolipid species were summed, and final levels are represented on the Y axis as pmol/nmol Pi. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.
Lastly, to see the effect of these changes in sphingolipid levels on the sensitivity to imatinib, we assessed a cell viability test with trypan blue exclusion assay to the cells treated with imatinib with or without eliglustat. As shown in Figure 3.46, imatinib and eliglustat alone treatments did not show any effect on cell viability at neither at 24 not at 48 h. Impressively, cotreatment of imatinib and eliglustat resulted in sensitization of SD-1R cells to imatinib treatment by showing a decrease in cell number by ~40% and ~70% at 24 and 48 h respectively. This data is suggesting that, a reversal in resistance to imatinib can be achieved by treating cells with eliglustat to inhibit GCS activity together with imatinib resulted by an accumulation in ceramide and sphingosine levels synergistically.

Figure 3.46. The effect of treatment with imatinib, eliglustat and their combination on cell viability of SD-1R cells. Cell viability is assessed by trypan blue exclusion assay for SD-1R cells seeded at 0.3x10^6 cells/ml and treated with vehicle (DMSO), imatinib (10μM), eliglustat (100nM) and eliglustat (100nM)+imatinib (10μM) for 24 and 48 h. The error bars represent the SD from 3 different experiments. ns P>0.05, *P<0.05, **P<0.01.

Finally, similar to the data obtained in SD-1 cells, to further prove that overcoming imatinib resistance is actually through GCS inhibition but not by any possible off-target effects of eliglustat, we repeated the viability assay by applying the same concentration of imatinib onto cells that are transfected by control and GCS siRNAs. The data showed that, indeed as eliglustat does, silencing GCS by siRNA is able to sensitize SD-1R cells to imatinib treatment whereas the cells transfected with control siRNA were unresponsive to imatinib treatment at the cell viability level (Figure 3.47).
Figure 3.47. Effect of GCS knockdown together with imatinib treatment on cell viability in SD-1R cells. Cell viability is assessed by trypan blue exclusion assay for SD-1 cells transfected with control and GCS siRNAs and then treated with imatinib (10 μM) for 24 hours. The error bars represent the standard deviation (SD) from 3 different experiments. Asterisks indicate statistical significance: ns P>0.05, *P<0.05, **P<0.01.

Taken together, these data reveal the involvement of sphingolipids by a defect in production of majorly ceramide and/or sphingosine into secondary resistance to imatinib as well as intrinsic imatinib resistance. Moreover, the data showed the reversal of imatinib resistance following modulation of sphingolipids with inhibiting GCS activity by eliglustat in order to accumulate ceramide and/or sphingosine to achieve cytotoxic levels of these sphingolipids in secondary resistant Ph+ ALL cells. All together these results suggest that lack of ceramide and/or sphingosine accumulation following imatinib treatment is associated with secondary resistance to imatinib in SD-1R cells and that blocking GCS activity was sufficient to cause the accumulation of these growth inhibitory sphingolipids and to re-sensitize SD-1R cells to imatinib.
CHAPTER 4

DISCUSSION

Ph+ ALL is the most commonly seen subtype of adult B-ALL with the incidence of 20-30% in adults. The prognosis has significantly improved after the approval of a first-generation TKI, imatinib mesylate as a first-line therapy in Ph+ ALL. Even monotherapy with TKIs have been shown to effective enough for the patients to reach complete remission in older patients; it also has been shown that using TKIs in combination with multi-agent chemotherapy led to disease free survival and better outcomes in long-term. Although the advancements in the prognosis of Ph+ ALL with the developments of new treatment options; the disease is still considered as high-risk with high risk of relapse and the overall survival rate is still around 30-45%. So far, development of imatinib resistance has been considered as one of the major mechanisms that cause the failure of treatment. In this regard, studies with second generation TKIs such as dasatinib, nilotinib and bosutinib showed that they might only partially overcome imatinib resistance in the patients with T315I mutation. Therefore, recent studies have been focused on discovering the signaling pathways that potentially contribute the development of resistance to eventually find targetable molecules in order to prevent the development of resistance from the beginning of the treatment or overcome the existent resistance.

Imatinib resistant Ph+ ALL cell lines have been shown to depend on alternative survival pathways other than BCR/ABL itself, including RAS/RAF/MEK pathway and PI3K/AKT pathway. Nevertheless, the roles of these pathways in imatinib resistant Ph+ ALL patients are not fully understood and the number of studies focusing on this issue remains limited. Therefore, our study carries importance in two major points: i) revealing the involvement of bioactive sphingolipids in imatinib induced growth inhibition in Ph+ ALL cells ii) introducing a new treatment strategy to reverse imatinib resistance by manipulating sphingolipid pathway.

To begin with, Ph+ ALL cell lines are known to be intrinsically more resistant to imatinib compared to CML cell lines due to their molecular complexity. Considering
this fact, between two different Ph+ ALL having different sensitivity to imatinib, we picked an intrinsically more resistant cell line SD-1 to start with in order to mimic the condition of intrinsically imatinib resistant patients (Figure 3.1). Another reason is that thinking the clinical relevance, intrinsically more resistant patients are more likely to develop secondary and stronger resistance to imatinib as they go through treatment, which is modeled in our newly generated SD-1R cells by using SD-1 cells as parental cell line (Figure 3.37).

On the other hand, bioactive sphingolipids and their regulation on the progression of cancer have been studied in various type of cancers previously. Sphingosine kinase, in particular has been shown to regulate imatinib induced apoptosis and resistant to imatinib through regulation of BCR/ABL in CML cell lines and in the most recent studies targeting sphingosine kinase-1 and -2 has been demonstrated as a new treatment strategy in Ph+ ALL. Interestingly, we could not detect any effect of SK-1 inhibition in addition to the effects of imatinib when applied together, suggesting the regulation of ceramide for the development of imatinib resistance can vary among different cell lines (Figure 3.7). Interestingly, SK-1 levels were significantly decreasing with imatinib treatment both at the activity level and the protein expression level (Figure 3.5 and 3.6) suggesting a highly possible relation between BCR/ABL and SK-1 in Ph+ ALL. On the other hand, SK-1 activity level did not change by doubling the concentration of PF543 from 400 nM to 800 nM, suggesting that PF543 was at maximal inhibitory concentration at 400 nM and the leftover SK activity is coming from SK-2 because PF543 is known to be specific for SK-1 (Figure 3.4). Another interesting point is that, imatinib and PF543 were adding onto SK-1 activity levels as shown in Figure 3.6 but the additive effect on SK-1 activity level did not reflect on cell number data in Figure 3.7. When we screened the previous studies revealing the roles of SK-1 into Ph+ ALL or CML, we realized that instead of PF543, SKI-II were used as a pharmacological inhibitor of SK. As Cingolani et al. reported, SKI-II were detected to inhibit dihydroceramide desaturase (DES) activity and as some of the effects seen by SKI-II attributed to decreased S1P could actually be caused by augmented dhCers and/or their metabolite instead of a direct result of only SK inhibition. Therefore, the same possibility should be taken into account in the case for Ph+ ALL after evaluating our results with previous reports.

On the other hand, other studies showed the involvement of ceramide into TKI induced cell death in CML cell lines. Our study is in agreement with the previous studies showing that the action of imatinib requires regulation of sphingolipid
metabolism. As shown in Figure 3.8-3.16, imatinib treatment resulted in an increase in the levels of dihydrosphingosine, dihydroceramide, most of the ceramide species, and sphingosine as well as complex sphingolipids including hexosylceramides and sphingomyelin; suggesting that not only generation of ceramide but further metabolization of it to HexCer and SM is initiated by imatinib treatment in these cells. On the other hand, the level of ceramide and other sphingolipids including the members of de novo synthesis pathway was not changed with imatinib treatment in SD-1R cells suggesting that there is a defect in induction of de novo synthesis pathway in SD-1R cells which might be one of the resistance mechanisms in these cells. As previously reported, imatinib treatment induces ceramide accumulation by activation of de novo synthesis pathway through regulating serine palmitoyltransferase long chain-1 SPTLC1 (SPT), the enzyme catalyzes the first and rate-limiting step reaction of de novo synthesis in CML cells. Thus, it is pointing the idea that the defect in de novo synthesis pathway in SD-1R cells might be due to dysregulation of serine palmitoyltransferase (SPT). Another possibility for the defect in de novo synthesis is the involvement of ceramide synthases (CerS1-6), the enzymes that catalyze the formation of ceramides from sphingoid base and their suppression in SD-1R cells as a resistance mechanism. Previously, reported by CerS genes are upregulated by TKI treatment in CML cell lines which supports the question as to whether there is a correlation between these genes and response to imatinib in Ph+ ALL. So, we are currently focused on addressing these possibilities to fully understand the mechanism of imatinib resistance in Ph+ ALL cells from sphingolipids perspective. Interestingly, imatinib treatment was able to increase HexCer levels in SD-1R cells in a similar manner with SD-1 cells; suggesting the possibility of GCS activity being at maximum rate in both cells. Apparently, these cells are using HexCer as a sink for ceramide to prevent accumulation of ceramide by a similar mechanism which previously reported in different leukemias.

The increase in the members of de novo synthesis pathway that is seen in SD-1 cells but not in SD-1R cells led us to test the involvement of this pathway in imatinib induced cytostaticity in SD-1 cells. With our findings; although the cytostatic effect of imatinib is not fully rely on sphingolipids (ceramide and/or sphingosine), we are able to show that sphingolipids are involved in part in imatinib induced cytotoxicity. Apart from to the previous studies, we showed that the action of imatinib on sphingolipids are through induction of de novo synthesis pathway proved by our data shown in Figure 3.17-3.22. Myriocin is a serine palmitoyltransferase inhibitor which inhibits the first and rate-
limiting step reaction of de novo synthesis pathway used in various studies 260. To prove the induction of de novo synthesis pathway by imatinib, we measured sphingolipid levels with imatinib treatment in presence of myriocin which blocks the first reaction of de novo synthesis pathway. Indeed, imatinib was not able to modulate same sphingolipids when myriocin is present in the media, proving that the changes in sphingolipids by imatinib treatment are due to induction of de novo synthesis pathway. We also showed that blocking the first step reaction of de novo synthesis by using myriocin protects the cells from imatinib induced cytotoxicity and suggesting that production of sphingolipids by induction of de novo synthesis pathway is in part involved in the cytostatic effects of imatinib. It should be noted that imatinib has multiple targets other than BCR/ABL in the cells 261 and given the detected and used relatively high IC50 value of imatinib (5 μM and 15 μM for SD-1 and SD-1R cells, respectively) in this study suggesting that by inhibiting de novo synthesis of sphingolipids it is only possible to rescue cells from the effects of one of the downstream signaling targets of imatinib.

Previous studies have revealed the mechanism of ceramide shunting through glucosylceramide by the enzyme GCS and the role of GCS activation in regulation of chemotherapy resistance in various type of cancers. So, blocking the generation of glucosylceramide by different agents has been proposed as an approach to restore sensitivity to these chemotherapeutics mainly by inducing the accumulation of ceramide to reach the cytotoxic levels 262–267. With the same sense of purpose, we manipulated sphingolipid metabolism in our cells to further accumulate ceramide to sensitize them to imatinib. Since imatinib treatment also increased the levels of hexosylceramides in both SD-1 and SD-1R cells, we aimed to block the conversion of ceramide to hexosylceramides by inhibiting GCS activity by using an FDA approved GCS inhibitor eliglustat which is used in the patients with Gaucher’s disease. Eliglustat has been shown to be highly tolerated in humans 246,268 and proposed to use in combinational treatments of GCS inhibition with chemotherapeutic agents 245,269. Indeed, we were able to see a further accumulation in certain type of sphingolipids including ceramide as well as sphingosine and sphingomyelin with eliglustat treatment in combination with imatinib although eliglustat by itself was not sufficient to increase ceramide levels. A class of previously developed glucosylceramide synthase inhibitors (PDMP and P4) has been shown to accumulate ceramide through other mechanisms independently from only inhibition of glucosylceramide levels 270. Our result with eliglustat here is contradictory to these data in the sense of inhibiting glucosylceramide accumulation without increasing ceramide
levels or inhibiting cell growth which makes eliglustat more selective and tolerated in healthy tissues. As confirmed with the data shown in Figure 3.26 and 3.29 for SD-1 and 3.44 and 3.45 for SD-1R the levels of ceramide and/or sphingosine accumulated in the cells with eliglustat and imatinib cotreatment was enough to sensitize the cells to imatinib treatment in SD-1 cells and to overcome secondary resistance to imatinib in SD-1R cells. In passing, it should be noted that as well as ceramide, sphingosine is known as its cytotoxic effects in the cells 271,272. So, the sensitization to imatinib might be due to further accumulation of either ceramide and/or sphingosine. The growth inhibitory effect of ceramide has been shown to be through a number of pathways including suppression of Akt, c-Myc and BCR/ABL signaling 230,273,274. Therefore, the growth inhibitory effect of eliglustat and imatinib due to ceramide accumulation could be due to suppression of one of the listed signaling pathways. Specific to Ph+ ALL, there are multiple molecular pathways playing critical roles for the orchestration of the progression of Ph+ ALL 275,276. PI3K/AKT signaling, as being one of them is reported as BCR/ABL independent resistance mechanism in Ph+ ALL cell lines 94 and proposed as the responsible mechanism for unresponsiveness to imatinib. This confrontation suggesting that the mechanism of sensitization to imatinib might be actually due to the effects of ceramide on AKT signaling rather than on BCR/ABL given the previously reported inhibitory effect of ceramide on AKT signaling 189.

Since there is still an appreciable amount of ceramide being converted to SM in response to imatinib and eliglustat cotreatment (Figure 3.28); considering this amount of ceramide as getting lost; a more effective approach to sensitize the cells to imatinib treatment would be to inhibit both GCS and SMS activities with imatinib treatment at the same time. The only obstacle for this approach is that currently even the most commonly used inhibitor D609 has been shown to have other targets besides SMS in the sphingolipid pathway which makes the readout of the effect of this inhibitor difficult and unreliable 277.

In this study, we reported the biological changes by using only one cell line (SD-1) and its resistant derivative (SD-1R) and we still do not know if these findings can be transitable to a subset or all imatinib resistant patients. Therefore, our follow-up projects include using primary cultures obtained from imatinib sensitive and resistant patients and testing the efficiency of imatinib and eliglustat treatment on these cell cultures as well as xenografting a panel of Ph+ ALL samples into mice and testing the antileukemic effects of eliglustat and imatinib cotreatment in animal models. On the other hand, we can extend
this approach on both CML and Ph+ ALL cases by establishing this approach as a tool against imatinib resistance.

In conclusion, here for the first time in the literature we showed that \textit{de novo} synthesis pathway of sphingolipids is involved in response to imatinib induced growth inhibition in Ph+ ALL cells. Moreover, it is revealed that manipulation of sphingolipid metabolism by inhibiting GCS together with conventional chemotherapy is promising for imatinib resistant patients in Ph+ ALL.
REFERENCES


23. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - Results of the


34. Ottmann OG, Pfeifer H, Cayuela J-M, et al. Nilotinib (Tasigna) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-


leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr. Cancer. 2014. doi:10.1002/cncr.28522


64. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset


75. Khorashad JS, De Melo VA, Fiegler H, et al. Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis.


85. Mahon FX, Hayette S, Lagarde V, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. *Cancer Res.* 2008. doi:10.1158/0008-5472.CAN-08-1008


87. Noro R, Gemma A, Miyanaga A, et al. PTEN inactivation in lung cancer cells and...
the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. *Int J Oncol.* 2007.


106. Shukla S, Robey RW, Bates SE, Ambudkar S V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. *Drug Metab Dispos*. 2009. doi:10.1124/dmd.108.024612

tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 2005. doi:10.1158/0008-5472.CAN-04-3303


156. Khan WA, Mascarella SW, Lewin AH, Wyrick CD, Carroll FL, Hannun YA. Use of


179. Smyth MJ, Perry DK, Zhang J, Poirier GG, Hannun YA, Obeid LM. prICE: A downstream target for ceramide-induced apoptosis and for the inhibitory action of


190. Venable ME, Lee JY, Smyth MJ, Bielawska A, Obeid LM. Role of ceramide in


201. Xie P, Shen YF, Shi YP, et al. Overexpression of glucosylceramide synthase in
\[\text{doi:10.1016/j.leukres.2007.07.006}\]

\[\text{doi:10.1016/j.bbalip.2008.06.002}\]

\[\text{doi:10.1038/sj.onc.1209834}\]

\[\text{doi:10.1084/jem.192.5.601}\]


\[\text{doi:10.1016/B978-0-12-394274-6.00007-8}\]

\[\text{doi:10.1038/leu.2008.95}\]

\[\text{doi:10.1038/sj.leu.2404386}\]

\[\text{doi:10.1007/s12185-008-0052-0}\]

\[\text{doi:10.1074/jbc.M109.072801}\]

\[\text{doi:10.1016/j.bbrc.2006.02.070}\]


275. Brown VI, Seif AE, Reid GSD, Teachey DT, Grupp SA. Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and


DATE OF BIRTH /PLACE: 04.08.1991 / Malatya, TURKEY

EDUCATION
PhD Izmir Institute of Technology – Molecular Biology and Genetics (2015-2019)
Visiting Research Scholar Stony Brook University – Health Science Center (2017-2019)
MSc Izmir Institute of Technology – Molecular Biology and Genetics (2015-2019)
Bachelor’s Degree Istanbul University – Molecular Biology and Genetics (2009-2013)

PUBLICATIONS

SELECTED AWARDS
1. “The Best Project Award” AMGEN 1st Biotechnology Fair, 2019
2. “Young Researcher Award” 45th Congress of Turkish Hematology Association, 2019
3. “Experimental Hematology Award” 45th Congress of Turkish Hematology Association, 2019
4. “EHA Travel Grant” 24th Congress of European Hematology Association, 2019
5. “Selected for International Research Fellowship Programme for Doctoral Students” TUBITAK, 2019
7. “Nejat F. Eczacıbaşı Scientific Project Support Award” 2015
8. “Qualified in a global competition among young scientists worldwide to participate in the 65th Lindau Nobel Laureate Meeting”, 2015.